# Patent

## Title
Compositions and methods for short interfering nucleic acid inhibition of Nav1.8

## Abstract

The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of priority under 35 USC 119(e) of provisional patent application U.S. Ser. No.: 60/622,484 filed Oct. 27, 2004, the disclosure of which is hereby incorporated by reference in its entirety.


BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain.
BACKGROUND OF THE INVENTION
Chronic pain is a major symptom of peripheral neuropathies, whether induced by AIDS, cancer chemotherapy, diabetes, or by direct physical trauma to the peripheral nerves. Such neuropathic pain is often highly debilitating and resistant to therapeutic intervention.
Animal models of neuropathic pain have suggested that a prominent feature in the maintenance of the neuropathic state is an abnormal, persistent hyperexcitability of the sensory afferent neurons within the peripheral nerve following injury. In addition, a common clinical finding is that broad-spectrum sodium channel blockers, such as lidocaine, can acutely suppress neuropathic pain. However, the relative contribution of individual sodium channel subtypes in neuropathic pain remains unclear.
Voltage-gated sodium channels are critical for the initiation and propagation of action potentials in neurons. In addition, these channels are involved in the regulation of neuronal excitability. Therefore, voltage-gated sodium channels play an important role in transmitting nociceptive information throughout both the peripheral and central nervous systems. Peripheral nerve injury causes sodium channels to accumulate in the membranes of primary afferents around the site of injury. This results in repetitive firing and an increase in excitability of both injured afferents and their uninjured neighbors. This increase in excitability appears to be critical for the expression of neuropathic pain.
At least ten different isoforms of sodium channels have been identified in the brain, neurons and striated muscles. The major component of sodium channels is the 260 kDa α-subunit, which forms the pore of the channel. The α-subunit is composed of four homologous domains, DI, DII, DIII and DIV, each of which is composed of six transmembrane segments, S1-S6. Most sodium channels associate with auxiliary β-subunits, β1-β4, which have an average molecular weight of 30 kDa. The β-subunits modulate the level of expression and gating of these channels.
Three sodium channel isoforms, Nav1.7, Nav1.8 and Nav1.9, are expressed primarily in the PNS. Nav1.7 is widespread in the peripheral nervous system, such that it is present in all types of dorsal root ganglion neurons, in Schwann cells and in neuroendocrine cells. Nav1.7 is sensitive to nanomolar amounts of tetrodotoxin. Nav1.8 is found only in sensory afferent nerves and neurons of the dorsal root ganglion and trigeminal ganglion. The Nav1.8 channel is highly resistant to tetrodotoxin, with an IC50 of greater than 50 μM. Nav1.9 is also expressed in small fibers of the dorsal root ganglion and trigeminal ganglion and is also resistant to nanomolar concentrations of tetrodotoxin, but is half maximally blocked by  ̃40 μM of tetrodotoxin.
Recent interest in the search for therapeutic targets in the treatment of pain has focused on the tetrodotoxin resistant sodium channels found in adult dorsal root ganglion neurons, a significant fraction of which are known to be pain-sensing ‘nociceptors’. One such sodium channel is Nav1.8, which was formerly known as PN3 or peripheral nerve sodium channel type 3. This channel has been found to be upregulated in the dorsal root ganglion in chronic pain states. In addition, the biophysical properties of Nav1.8 make this channel a likely candidate for maintaining the sustained repetitive firing of the peripheral neuron following injury. Moreover, the expression of Nav1.8 being restricted to the periphery in sensory neurons of the dorsal root ganglion, suggests that blockade of this channel might allow relief from neuropathic pain with minimal side effects. However, this possibility can not be tested pharmacologically because currently available sodium channel blockers do not distinguish between sodium channel subtypes.
Antisense oligodeoxynucleotide targeting of Nav1.8 expression in an animal model of neuropathic pain has been employed to test whether a selectively attenuated expression of this channel might allow relief from neuropathic pain. See Porreca et al., “A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain”, Proc. Nat. Acad. Sci., vol. 96, pp. 7640-7644 (1999). Inhibition of Nav1.8 expression using antisense deoxyoligonucleotides has also been found to inhibit chronic pain in other animal pain models. See Yoshimura et al., “The involvement of the tetrodotoxin-resistant sodium channel Nav1.8 (PN3/SNS) in a rat model of visceral pain”, J. Neuroscience, vol. 21, pp. 8690-8696 (2001); and Khasar et al., “A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat”, Neuroscience Letters, vol. 256, no. 1, pp. 17-20 (1998). Further data indicate that selective knock-down of Nav1.8 protein in the dorsal root ganglion neurons by specific antisense oligodeoxynucleotides to Nav1.8 prevented the hyperalgesia and allodynia caused by spinal nerve ligation injury. See Kim et al., “An experimental model for peripheral neuopathy produced by segmental spinal nerve ligation in the rat”, Pain, vol. 50, pp. 355-363 (1992). The above data suggests a pathophysiological role for Nav1.8 in several peripheral neuropathic and inflammatory states.
However, the use of antisense oligodeoxynucleotides as therapeutics is limited by their instability in vivo, by their limited efficacy and by their tendency to produce ‘off-target’ effects. Since no small molecule has been identified that is capable of specifically blocking Nav1.8, there is a continued need for alternative ways of modulating Nav1.8 in the treatment of pain.
The present invention meets the above need by providing short interfering nucleic acids and siRNAs to specifically knock-down expression of Nav1.8. The use of siRNA is attractive because it has high target specificity, reduced off-target liability and achieves high levels of suppression. siRNA, which stands for short interfering RNA or small interfering RNA, is a form of RNA interference (RNAi). RNAi is a technique used to investigate gene function by degrading a specific mRNA target in a cell, thus knocking-out or knocking-down the level of the encoded protein. The mechanism of action of siRNA is thought to involve a multi-step process. First, double-stranded RNA (dsRNA) is recognized by an RNase III family member and is cleaved into siRNAs of 21 to 23 nucleotides. Next, the siRNAs are incorporated into an RNAi targeting complex called RNA-induced silencing complex (RISC). RISC is a dual function helicase and RNase that recognizes target mRNA. After recognizing a target mRNA, the RISC binds the mRNA and unwinds the siRNA, which allows the antisense strand of the siRNA to bind via complementary base pairing (Watson-Crick base pairing) to the target mRNA. This causes hydrolysis and destruction of the mRNA, which results in decreased protein expression. Furthermore, siRNA is apparently recycled such that one siRNA molecule is capable of inducing cleavage of approximately 1000 mRNA molecules. Therefore, siRNA-mediated RNAi is more effective than other currently available technologies for inhibiting expression of a target gene.
All references, publications, patent applications and patents disclosed herein are hereby incorporated by reference in their entirety.
BRIEF SUMMARY OF THE INVENTION
The present invention is directed to short interfering nucleic acids that specifically target and cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene and methods of using such short interfering nucleic acids.
An embodiment of the invention provides an isolated or recombinant short interfering nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, or an analogue thereof. The isolated or recombinant short interfering nucleic acid may further comprise a 3′ overhang. Also provided is a pharmaceutical composition comprising one or more of any of the above short interfering nucleic acids and a pharmaceutically acceptable carrier.
An alternative embodiment of the invention provides an isolated or recombinant short interfering nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, or an analogue thereof, and further comprising a complementary nucleotide sequence thereto. The isolated or recombinant short interfering nucleic acid may further comprise a 3′ overhang. Also provided is a pharmaceutical composition comprising one or more of any of the above short interfering nucleic acids and a pharmaceutically acceptable carrier.
Another embodiment provides an isolated or recombinant short interfering nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, or an analogue thereof, and further comprising a complementary nucleotide sequence thereto, wherein the nucleotide sequence and the complementary nucleotide sequence hybridize to form a duplex. The nucleotide sequence and the complementary nucleotide sequence may each further comprise a 3′ overhang. Also provided is a pharmaceutical composition comprising one or more of any of the above duplexes and a pharmaceutically acceptable carrier.
An additional embodiment provides an isolated or recombinant short interfering nucleic acid comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand hybridize to form a duplex, wherein the sense strand comprises a nucleotide sequence substantially identical to a target sequence, and wherein the target sequence is selected from the group consisting of SEQ ID NOs: 12-577. The sense strand and the antisense strand may each further comprise a 3′ overhang. Also provided is a pharmaceutical composition comprising one or more of any of the above duplexes and a pharmaceutically acceptable carrier.
An embodiment of the invention provides a recombinant vector comprising one or more of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, or an analogue thereof.
Another embodiment provides a method for inhibiting translation of an mRNA to a polypeptide comprising contacting a cell capable of expressing a Nav1.8 mRNA with one or more isolated or recombinant short interfering nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, or an analogue thereof.
An alternative embodiment provides a method for inhibiting expression of a polypeptide comprising contacting a cell capable of expressing a Nav1.8 polypeptide with one or more isolated or recombinant short interfering nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, or an analogue thereof.
Another alternative embodiment provides a method for blocking the Nav1.8 derived membrane potential in a cell comprising contacting a cell expressing a Nav1.8 polypeptide, with one or more isolated or recombinant short interfering nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, or an analogue thereof.
An additional embodiment provides a method for blocking the Nav1.8 derived sodium ion flux in a cell comprising contacting a cell expressing a Nav1.8 polypeptide with one or more isolated or recombinant short interfering nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, or an analogue thereof.
A further embodiment provides a method for inhibiting chronic pain comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more isolated or recombinant short interfering nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11, or an analogue thereof, and a pharmaceutically acceptable carrier. The above isolated or recombinant short interfering nucleic acid may further comprise a 3′ overhang.


DETAILED DESCRIPTION OF THE INVENTION
All publications cited herein are incorporated by reference in their entirety.
Definitions
The term “antisense strand”, as used in this application, means a nucleic acid sequence that is complementary to a sense strand.
The term “chronic pain”, as used in this application, is defined as pain that lasts for a long period of time
The term “complementary”, as defined in this application, means a nucleotide sequence that exhibits Watson-Crick base pairing with another nucleotide sequence, i.e., a purine binds to a pyrimidine. For example, a nucleotide sequence may represent a sense strand while the complementary nucleotide sequence thereto may represent the antisense strand.
The term “duplex”, as used herein, means two complementary nucleic acid sequences that have hybridized, such as a sense strand and an antisense strand.
The terms “express”, “expresses” and “expression”, as used herein, mean the molecular biological process by which transcription and translation of a nucleic acid produce a polypeptide, i.e., the process by which genetic information flows from genes to proteins, and by which the effects of genes are manifested.
The terms “homology” and “homologous” refer to a comparison between two nucleic acid sequences, such that when the sequences are aligned and compared, they exhibit similarities. Homology between two nucleic acid sequences can be determined by sequence comparison or based upon hybridization conditions. Nucleotide sequence homology is observed when there is identity in nucleotide residues in two sequences (or in their complementary strands) when optimally aligned to account for nucleotide insertions or deletions. Homology also exists when one nucleotide sequence will hybridize to another sequence under selective hybridization conditions. Stringency of conditions employed in hybridizations to establish homology are dependent upon such factors as salt concentration, temperature, the presence of organic solvents, and other parameters.
The term “knock-down”, as used in this application, means to decrease the level of expression of mRNA, such that translation of mRNA to protein is diminished.
The term “knock-out”, as defined in this application, means to prevent expression of mRNA, such that translation of mRNA to protein does not occur.
The term “mRNA”, as used herein, means messenger RNA.
The term “membrane potential”, as used herein, means the difference in electrical charge across both sides of a cell membrane.
The term “pain”, as used in this application, means physical pain, such as an uncomfortable sensation in the body, ranging from slight uneasiness to extreme distress or torture, that is usually the result of disease, injury or stress; or mental pain, such as uneasiness of the mind, mental distress, anguish, anxiety or grief.
The term “RNAi”, as used in this application, means RNA interference, which is a technique used to investigate gene function by degrading a specific mRNA target in a cell or organism, thus knocking-out or knocking-down the level of the encoded protein. This is also referred to as RNA silencing.
The term “sense strand”, as used in this application, means the coding strand of a nucleic acid.
The term “siRNA”, as used in this application, means either short or small interfering ribonucleic acid, which is one of the types of RNA silencing mechanisms of RNA interference.
The term “short interfering nucleic acid”, as defined in this application, means short interfering stretches of either deoxyribonucleic acids (DNA), ribonucleic acids (RNA) or combinations of both. The term also includes modifications to the nucleic acids and non-traditional bases. Preferably, the short interfering nucleic acid is an siRNA.
The term “sodium current”, as used herein, means the part of a cell's membrane potential that is due to the effects of sodium ions, The term “subject” means both human and non-human animals.
The term “transfect”, as used in this application, means the introduction of a nucleic acid into a cell, such as through the use of a virus.
The term “transcription”, as defined in this application, means the molecular biological process by which a single-stranded RNA is synthesized from a double-stranded DNA.
The term “translation”, as used in this application, means the molecular biological process by which a polypeptide is synthesized from a mRNA.
The term “treatment”, as defined herein, means therapeutic, prophylactic or suppressive measures for a disease or disorder leading to any clinically desirable or beneficial effect, including, but not limited to, alleviation of one or more symptoms, regression, slowing or cessation of progression of the disease or disorder.
Nav1.8 Characterization
The Nav1.8 sodium channel comprises an alpha subunit and at least one beta subunit. The nucleotide sequence of the complete open reading frame and the corresponding amino acid sequence of Nav1.8 are known in the art. For example, both the nucleic acid and the amino acid sequence for rat Nav1.8 may be found in SEQ ID NOs: 1 and 2, respectively, of U.S. Pat. No. 6,451,554. The nucleic acid sequence and amino acid sequence for Nav1.8 and its subunits may also be found in the GenBank® database, as shown in Table 1 below.











TABLE 1








GenBank ® No. for
GenBank ® No. for



species
Nucleic Acid Sequence
Amino Acid Sequence









rat
NM 017247
NP 058943



human
AF 117907
AAD 30863










The human Nav1.8 gene has a high degree of homology, approximately 82%, with the rat Nav1.8 gene. Therefore, human Nav1.8 short interfering nucleic acids corresponding to rat Nav1.8 short interfering nucleic acids that are capable of knock-down of the rat Nav1.8 sodium channel are likely to be effective in the knock-down of the human Nav1.8 sodium channel.

Nucleic Acids

Compositions and methods comprising short interfering nucleic acids targeted to Nav1.8 mRNA are advantageously used to knock-down or knock-out expression of the Nav1.8 sodium channel for the treatment of chronic pain. Specifically, the short interfering nucleic acids of the invention cause RNAi-mediated destruction of the Nav1.8 mRNA.
The Nav1.8 sodium channel is upregulated in the dorsal root ganglion in chronic pain states. Therefore, short interfering nucleic acid sequences capable of knocking-down or knocking-out the expression of Nav1.8 mRNA, as well as Nav1.8 function should be useful in blocking or treating chronic pain.
The present invention, therefore, provides isolated or recombinant short interfering nucleic acids. As used herein, the term “isolated” means a nucleic acid, such as an RNA or DNA molecule, or a mixed polymer, which is substantially separated from other components that are normally found in cells or in recombinant expression systems. These components include, but are not limited to, ribosomes, polymerases, serum components, and flanking genomic sequences. The term thus embraces a short interfering nucleic acid that has been removed from its naturally occurring environment, and includes recombinant or cloned short interfering nucleic acid isolates and chemically synthesized analogs or analogs biologically synthesized by heterologous systems. A substantially pure molecule includes isolated forms of the molecule.
An isolated nucleic acid will generally be a homogeneous composition of molecules but may, in some embodiments, contain minor heterogeneity. Such heterogeneity is typically found at the ends of nucleic acid coding sequences or in regions not critical to a desired biological function or activity.
A “recombinant” short interfering nucleic acid is defined either by its method of production or structure. Some recombinant nucleic acids are thus made by the use of recombinant DNA techniques that involve human intervention, either in manipulation or selection. Others are made by fusing two fragments that are not naturally contiguous to each other. Engineered vectors are encompassed, as well as nucleic acids comprising sequences derived using any synthetic oligonucleotide process.
The short interfering nucleic acids may be either single-stranded or double-stranded. A single-stranded short interfering nucleic acid comprises a sense strand while a double-stranded short interfering nucleic acid comprises both a sense strand and an antisense strand. Preferably, the sense and antisense strands in the double-stranded short interfering nucleic acids hybridize by standard Watson-Crick base-pairing interactions to form a duplex or are connected by a single-stranded hairpin area. It is believed that the hairpin area of the latter type of siRNA molecule is cleaved intracellularly by the “Dicer” protein, or its equivalent, to form an siRNA of two individual base-paired RNA molecules.
The short interfering nucleic acids may range in length from 17 to 29 nucleotides, preferably 19 to 25 nucleotides, more preferably 21-23 nucleotides, and most preferably 21 nucleotides.
Preferably, the short interfering nucleic acid is an siRNA. That is, all of the nucleotides in the sequence are ribonucleotide bases.
However, the present invention also encompasses analogues of the small interfering nucleic acids. Analogues of short interfering nucleic acids contain additions, deletions, alterations, substitutions or modifications of one or more nucleotide bases. For example, the short interfering nucleic acids can be altered, substituted or modified to contain one or more deoxyribonucleotide bases or non-traditional bases or any combination of these.
Preferably, one or both strands of a short interfering nucleic acid of the invention comprises a 3′ overhang. As used herein, a “3′ overhang” refers to at least one unpaired nucleotide extending from the 3′-end of a short interfering nucleic acid strand. The 3′ overhang may range from 1 to 6 nucleotides (which includes ribonucleotides or deoxyribonucleotides), preferably from 1 to 5 nucleotides, more preferably from 1 to 4 nucleotides, particularly preferably from 2 to 4 nucleotides, and most preferably 2 nucleotides.
In another embodiment of the invention, both the sense and antisense strands of the duplex comprise 3′ overhangs. The length of the overhangs can be the same or different for each strand of the duplex. Most preferably, a 3′ overhang is present on both strands of the duplex, and the overhang for each strand is 2 nucleotides in length. For example, each strand of the duplex can comprise 3′ overhangs of dithymidylic acid (“tt”) or diuridylic acid (“uu”).
In order to enhance the stability of the short interfering nucleic acids, the 3′ overhangs can also be stabilized against degradation. In one embodiment, the 3′ overhangs are stabilized by including purine nucleotides, such as adenosine or guanosine nucleotides. Alternatively, substitution of pyrimidine nucleotides by modified analogues, e.g., substitution of uridine nucleotides in the 3′ overhangs with 2′-deoxythymidine, is tolerated and does not affect the efficiency of RNAi degradation. In particular, the absence of a 2′ hydroxyl in the 2′-deoxythymidine significantly enhances the nuclease resistance of the 3′ overhang in tissue culture medium.
The short interfering nucleic acids are targeted to a Nav1.8 target mRNA. As used herein, short interfering nucleic acids that are “targeted to a Nav1.8 target mRNA” means either a single-stranded or double-stranded short interfering nucleic acid in which the sense strand has a nucleotide sequence that is either identical or substantially identical to that of a target mRNA and is capable of inducing RNAi-mediated degradation of the mRNA. Of course, the antisense strand of a double-stranded siRNA will have a sequence that is complementary to both the sense strand of the siRNA and the target mRNA.
As used herein, a short interfering nucleic acid that is “substantially identical” to a target sequence is a nucleic acid sequence that differs from the target sequence by 1-4 nucleotides. For example, a short interfering nucleic acid may comprise a sense strand that differs from a target sequence by one, two, three or four nucleotides, as long as RNAi-mediated degradation of the target mRNA is induced by the short interfering nucleic acid.
As used herein, “target mRNA” or “target sequence” means human Nav1.8 mRNA, mutant or alternative splice forms of Nav1.8 mRNA, or mRNA from cognate Nav1.8 genes. The term “mutant”, as used herein, means a short interfering nucleic acid that differs from the target mRNA by having a nucleotide insertion, nucleotide deletion, nucleotide substitution or nucleotide modification. Such alterations can include, for example, the: addition of non-nucleotide material, such as to the end(s) of the short interfering nucleic acids or to one or more internal nucleotides of the short interfering nucleic acids; modifications that make the short interfering nucleic acids resistant to nuclease digestion; or substitution of one or more nucleotides in the short interfering nucleic acids with deoxyribonucleotides. The term “cognate”, as used herein, means a nucleic acid from another mammalian species. It is understood that human Nav1.8 mRNA may contain target sequences in common with their respective cognates or mutants. A single short interfering nucleic acid comprising such a common targeting sequence can therefore induce RNAi-mediated degradation of different RNA types that contain the common targeting sequence.
The short interfering nucleic acid of the invention can be targeted to any stretch of approximately 19-25 contiguous nucleotides in any target mRNA sequence. Techniques for selecting target sequences for short interfering nucleic acids are known in the art. In addition, a target sequence on the target mRNA can be selected from a given cDNA sequence corresponding to the target mRNA, preferably beginning 50 to 100 nucleotides downstream, i.e., in the 3′ direction, from the start codon. The target sequence can, however, be located in the 5′ or 3′ untranslated regions, or in the region nearby the start codon. Suitable target sequences in the Nav1.8 cDNA sequence are given in Example 1.
The short interfering nucleic acid of the invention can comprise partially purified nucleic acid, substantially pure nucleic acid, synthetic nucleic acid or recombinantly produced nucleic acid. The term “substantially pure” is defined herein to mean a short interfering nucleic acid that is free from other contaminating proteins, nucleic acids, and other biologicals derived from an original source organism or recombinant DNA expression system. Purity may be assayed by standard methods and will typically exceed at least about 50%, preferably at least about 75%, more preferably at least about 90%, and most preferably at least about 95% purity. The purity evaluation may be made on a mass or molar basis.
The short interfering nucleic acids of the invention can be obtained using any one of a number of techniques known to those of skill in the art. In addition, the short interfering nucleic acids may also be synthesized as two separate, complementary nucleic acid molecules, or as a single nucleic acid molecule with two complementary regions. For example, the short interfering nucleic acids of the invention are chemically synthesized using appropriately protected ribonucleoside phosphoramidites and a conventional DNA/RNA synthesizer or other well known methods. In addition, the short interfering nucleic acids may be produced by a commercial supplier, such as Proligo (Hamburg, Germany), Dharmacon Research (Lafayette, Colo., USA), Pierce Chemical (part of Perbio Science, Rockford, Ill., USA), Glen Research (Sterling, Va., USA), ChemGenes (Ashland, Mass., USA) and Cruachem (Glasgow, UK).
Alternatively, short interfering nucleic acids may also be expressed from a recombinant expression vector, such as a circular or linear DNA plasmid, using any suitable promoter. Recombinant expression vectors are typically self-replicating DNA or RNA constructs comprising nucleic acids encoding one of the short interfering nucleic acids, usually operably linked to suitable genetic control elements that are capable of regulating expression of the nucleic acids in compatible host cells. Genetic control elements may include a prokaryotic promoter system or a eukaryotic promoter expression control system, and typically include a transcriptional promoter, an optional operator to control the onset of transcription, transcription enhancers to elevate the level of mRNA expression, a sequence that encodes a suitable ribosome binding site, a translation initiation site, a polyadenylation site, sequences that terminate transcription and translation. Expression vectors may also contain an origin of replication that allows the vector to replicate independently of the host cell, or a selection gene, such as a gene conferring resistance to an antibiotic.
Vectors that could be used in this invention include microbial plasmids, viruses, bacteriophage, integratable DNA fragments, and other vehicles that may facilitate integration of the nucleic acids into the genome of the host. Plasmids are a commonly used form of vector, but all other forms of vectors that serve an equivalent function and which are, or become, known in the art are suitable for use herein. See, e.g., Pouwels et al., Cloning Vectors: A Laboratory Manual, 1985 and Supplements, Elsevier, N.Y., and Rodriguez et al. (eds.), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, 1988, Buttersworth, Boston, Mass.
Suitable promoters for expressing short interfering nucleic acids of the invention from a plasmid include, for example, the U6 promoter, the H1 RNA pol III promoter, and the cytomegalovirus promoter. Selection of other suitable promoters is within the skill in the art. The recombinant plasmids of the invention may also comprise an inducible or regulatable promoter for expression of the short interfering nucleic acid in a particular tissue or in a particular intracellular environment.
The short interfering nucleic acid expressed from recombinant plasmids may either be isolated from cultured cell expression systems by standard techniques, or can be expressed intracellularly. The short interfering nucleic acid of the invention can be expressed from a recombinant plasmid either as two separate, complementary RNA molecules, or as a single RNA molecule with two complementary regions. Selection of plasmids suitable for expressing short interfering nucleic acids of the invention, methods for inserting nucleic acid sequences for expressing the short interfering nucleic acids into the plasmid, and methods of delivering the recombinant plasmid to the cells of interest are within the skill in the art. See, for example, Tuschl, Nat. Biotechnol, vol. 20, pp. 446-448 (2002); Brummelkamp et al., Science, vol. 296, pp. 550-553 (2002); Miyagishi et al., Nat. Biotechnol., vol. 20, ppl. 497-500 (2002); Paddison et al., Genes Dev., vol. 16, pp. 948-958 (2002); Lee et al., Nat. Biotechnol., vol. 20, pp. 500-505 (2002); Paul et al., Nat. Biotechnol., vol. 20, pp. 505-508 (2002); and Sui et al., Proc. Natl. Acad. Sci. vol 99, 2002, pp 5515-5520).
By way of example, a plasmid may comprise a sense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter, and an antisense RNA strand coding sequence in operable connection with a polyT termination sequence under the control of a human U6 RNA promoter.
As used herein, “in operable connection with” means that the nucleic acid sequences encoding the sense or antisense strands are adjacent to another sequence. Preferably, the sequence encoding the sense or antisense strands are immediately adjacent to the poly T termination signal in the 5′ direction. Therefore, during transcription of the sense or antisense sequences from the plasmid, the polyT termination signals act to terminate transcription.
As used herein, “under the control of a promoter” means that the nucleic acid sequences encoding the sense or antisense strands are located 3′ of the promoter, so that the promoter can initiate transcription of the sense or antisense coding sequences.
Expression of the short interfering nucleic acids can be carried out by conventional methods in either prokaryotic or eukaryotic cells. Prokaryotes include both gram negative and positive organisms, e.g., E. coli and B. subtilis. Higher eukaryotes include established tissue culture cell lines from animal cells, both of non-mammalian origin, e.g., insect cells, and birds, and of mammalian origin, e.g., human, primates, and rodents. Many suitable host cells are known in the art. Preferred host cells are HEK293 cells and the neuroblastoma/DRG cell line ND7/23.
The short interfering nucleic acids of the invention may also be expressed from recombinant viral vectors. The recombinant viral vectors of the invention comprise sequences encoding the short interfering nucleic acids of the invention and any suitable promoter for expressing the short interfering nucleic acid sequences. Suitable promoters for expressing short interfering nucleic acids from a viral vector include, for example, the U6 promoter, the H1 RNA pol III promoter, and the cytomegalovirus promoter. Selection of other suitable promoters is within the skill in the art. The recombinant viral vectors of the invention can also comprise inducible or regulatable promoters for expression of the short interfering nucleic acids in a particular tissue or in a particular intracellular environment. The use of recombinant viral vectors to deliver short interfering nucleic acids of the invention to cells in vivo is discussed in more detail in Example 5.
The short interfering nucleic acids of the invention can be expressed from a recombinant viral vector either as two separate, complementary nucleic acid molecules, or as a single nucleic acid molecule with two complementary regions.
Any viral vector capable of accepting the coding sequences for the short interfering nucleic acid molecule(s) to be expressed can be used, such as, vectors derived from adenovirus (AV), adeno-associated virus (AAV), retroviruses, herpes virus, and the like. In addition, the tropism of the viral vectors may also be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses.
Selection of recombinant viral vectors suitable for use in the invention, methods for inserting nucleic acid sequences for expressing the short interfering nucleic acids into the vector, and methods of delivering the viral vector to the cells of interest are within the skill in the art. See, for example, Domburg, Gene Therap., vol. 2, pp. 301-310 (1995); Eglitis, Biotechniques, vol. 6, pp. 608-614 (1988); Miller, Hum Gene Therap., vol. 1, pp. 5-14 (1990); and Anderson, Nature, vol. 392, pp. 25-30 (1998).
Preferred viral vectors are those derived from adenovirus and adeno-associated virus. In a particularly preferred embodiment, a short interfering nucleic acid of the invention is expressed as a single-stranded nucleic acid molecule from a recombinant adenoviral vector comprising the U6 promoter. Preferred viral vectors are also herpes viral vectors. See for e.g., Burton, E. A. et al., (2005) Curr. Opin. Mol. Ther. August: 7(4):326-36 and Yeomans D. D. et al .(2005)—Hum Gene Therap February :16(2):271-7. By way of example, and not limitation, the expressed single stranded nucleic acid molecule can comprise two complementary regions connected by a single stranded hairpin area. The single stranded nucleic acid molecule can further comprise a 3′ overhang.
In Vitro and In Vivo Methods
The ability of a short interfering nucleic acid to cause RNAi-mediated degradation of the target mRNA can be evaluated using standard techniques for measuring the levels of RNA or protein in cells. For example, short interfering nucleic acids may be delivered to cultured cells, and the levels of target mRNA can be measured by Northern blot, dot-blotting techniques, or by quantitative RT-PCR. Alternatively, the levels of Nav1.8 protein in the cultured cells can be measured by ELISA or Western blot. A suitable cell culture system for measuring the effect of the present short interfering nucleic acids on target mRNA or protein levels is described in Example 2 below.
As discussed above, the short interfering nucleic acids of the invention targets and causes the RNAi-mediated degradation of Nav1.8 mRNA, or alternative splice forms, mutants or cognates thereof. Degradation of the target mRNA by the present short interfering nucleic acids reduces the production of a functional gene product from the Nav1.8 gene. Thus, the invention provides a method of inhibiting expression of Nav1.8 in a subject, a method for inhibiting translation of an mRNA, a method for inhibiting expression of a polypeptide, a method for blocking the Nav1.8 derived membrane potential in a cell, and a method for blocking the Nav1.8 derived sodium current in a cell. In the methods of the invention, blocking includes, but is not limited to an abolition or reduction in the Nav1.8 derived membrane potential or the Nav1.8 derived sodium current Although these methods are more thoroughly detailed in the Examples, they all share a few common characterisitics.
A step of each of the above methods involves contacting a cell with a short interfering nucleic acid. In vivo, the contacting step involves administering a short interfering nucleic acid in a pharmaceutical composition to a subject. In vitro, the contacting step involves bringing the cell and short interfering nucleic acid into close physical proximity such that the cell and the short interfering nucleic acid may contact each other. This contacting step will allow the short interfering nucleic acid to enter the cell and cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene.
Preferably, the contacting step utilizes the short interfering nucleic acids of SEQ ID NOs: 1-11. The short interfering nucleic acids of SEQ ID NOs: 1, 2, 3, 5, 10 and 11 are preferable. The short interfering nucleic acids of SEQ ID NOs: 2 and 5 are more preferable. The short interfering nucleic acids of SEQ ID NOs: 1 and 3 are the most preferable. One or more of the short interfering nucleic acids of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 can also be utilized in the methods of the invention. By way of example, and not limitation, one or more of the short interfering nucleic acids of SEQ ID NOs; 1, 2, 3, 5, 10 and 11 can be used in the methods of the invention. Furthermore, in the practice of the present methods, it is understood that more than one short interfering nucleic acids of the invention can be administered simultaneously or sequentially to a cell or to a subject. This invention further provides the short interfering nucleic acids of the invention complexed with one or more proteins and/or target nucleic acid and a cell comprising one or more short interfering nucleic acids of the invention.
Pharmaceutical Compositions
The short interfering nucleic acids and siRNAs of the present invention can be used therapeutically to treat chronic pain. Various compounds of the present invention may be incorporated into pharmaceutical compositions. For example, a pharmaceutical composition may comprise a single-stranded short interfering nucleic acid, a single-stranded short interfering nucleic acid that has a 3′ overhang, a double-stranded short interfering nucleic acid, or a double-stranded short interfering nucleic acid wherein each strand has a 3′overhang. Preferably, the pharmaceutical composition comprises the short interfering nucleic acids of SEQ ID NOs: 1-11. The short interfering nucleic acids of SEQ ID NOs: 2 and 5 are more preferable, while the short interfering nucleic acids of SEQ ID NOs: 1 and 3 are the most preferable. One or more of the short interfering nucleic acids of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 can also be utilized in the pharmaceutical compositions of the invention. By way of example, and not limitation, one or more of the short interfering nucleic acids of SEQ ID NOs; 1, 2, 3, 5, 10 and 11 can be used in the pharmaceutical compositions of the invention.
Typical protocols for the therapeutic administration of such substances are well known in the art. Although the compositions of the present invention may be administered in simple solution, they are more typically administered in combination with other materials, such as carriers, preferably pharmaceutical acceptable carriers. The term “pharmaceutically acceptable carrier” means any compatible, non-toxic substance that is suitable for delivering the compositions of the invention to a subject. For example, sterile water, alcohol, fats, waxes, and inert solids may be included in a carrier. Pharmaceutically acceptable adjuvants, such as buffering agents and dispersing agents, may also be incorporated into the pharmaceutical composition. Generally, compositions useful for parenteral administration of such drugs are well known; e.g. Remington's Pharmaceutical Science, 17th Ed. (Mack Publishing Company, Easton, Pa., 1990).
Therapeutic formulations may be administered. Formulations typically comprise at least one active ingredient, together with one or more pharmaceutically acceptable carriers. Formulations may include those suitable for oral, rectal, nasal, transdermal, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman et al. (eds.) (1990), The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, supra, Easton, Pa.; Avis et al. (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications Dekker, N.Y.; Lieberman et al. (eds.) (1990) Pharmaceutical Dosage Forms: Tablets Dekker, N.Y.; and Lieberman et al. (eds.) (1990), Pharmaceutical Dosage Forms: Disperse Systems Dekker, N.Y.
By way of example, any of the short interfering nucleic acids or vectors of the invention may be deliverable transdermally. The transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose. See, e.g. Remington's Pharmaceutical Science, 17th Ed. (Mack Publishing Company, Easton, Pa., 1990).
The dosage regimen involved in a therapeutic application will be determined by the attending physician, considering various factors that may modify the action of the therapeutic substance, e.g., the condition, body weight, sex and diet of the patient, the severity of any infection, time of administration, and other clinical factors. Often, treatment dosages are titrated upward from a low level to optimize safety and efficacy. Generally, daily dosages will fall within a range of 100-500 μg per kilogram of body weight. Typically, the dosage range will be 150-250 μg per kilogram of body weight. Preferably, the dosage will be 200 μg per kilogram of body weight. Dosages may be adjusted to account for the smaller molecular sizes and possibly decreased half-lives (clearance times) following administration. An “effective amount” of a composition of the invention is an amount that will ameliorate chronic pain in a subject.
Chronic pain may include one or more of the following characteristics: pain present for about three or more months, pain that is not fully relieved by routine medical management or pain that continues beyond a normal recovery period. Examples of chronic pain include, but are not limited to, chronic neuropathic pain and chronic inflammatory pain. Examples of chronic neuropathic and/or chronic inflammatory conditions, include, but are not limited to, post-herpetic neuralgia, painful diabetic neuropathy, radiculopathy, nerve compression injuries (e.g., carpal tunnel syndrome, trigeminal neuralgia, tumor-related nerve compressions), upper and low back pain (e.g., arising from disc herniation injuries, ankylosing spondylitis or cases of unknown pathology), complex regional pain syndromes types I and II, nerve trauma pain (e.g., phantom-limb pain, other painful conditions resulting from limb amputation), nerve-root avulsion injuries, HIV-associated pain, neuropathies arising from chemotherapeutic strategies, retinopathies, sciatica, hyperalgesia, hyperpathia and ongoing burning pain (e.g., wound-associated pain, including, but not limited to post-operative pain), joint pain, rheumatoid and osteoarthritis pain, fibromyalgia, burn pain, neuritis, sciatica, tendonitis, bone pain, migraine pain, urinogenital pain and neuropathic conditions attributed to bladder hyperreflexia.
EXAMPLES
The present invention may be better understood by reference to the following non-limiting examples, which are provided as exemplary of the invention. The following examples are presented in order to more fully illustrate the invention, and should in no way be construed as limiting the broad scope of the invention. Unless otherwise indicated, percentages given below for solids in solid mixtures, liquids in liquids, and solids in liquids are on a wt/wt, vol/vol and wt/vol basis, respectively. Sterile conditions were generally maintained during cell culture.
Materials and General Methods
Standard molecular biological methods were used, as described, e.g., in Maniatis et al., Molecular Cloning: A Laboratory Manual, 1982, Cold Spring Harbor Laboratory, Cold Spring Harbor Press; Sambrook et al., Molecular Cloning:A Laboratory Manual, (2d ed.), Vols 1-3, 1989, Cold Spring Harbor Press, N.Y.; Ausubel et al., Biology, Greene Publishing Associates, Brooklyn, N.Y.; or Ausubel, et al. (1987 and Supplements), Current Protocols in Molecular Biology, Greene/Wiley, N.Y.; and Innis et al. (eds.) PCR Protocols: A Guide to Methods and Applications, 1990, Academic Press, N.Y.
Example 1
This example illustrates the design of siRNAs against Nav1.8. Putative siRNA sequences against both rat and human Nav1.8 coding sequences were identified using Tuschl's prediction rules. See Tuschl et al., “Targeted mRNA degradation by double-stranded RNA in vitro”, Genes Dev., vol. 13, no. 24, pp. 3191-3197 (Dec. 15, 1999); and Elbashir et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells”, Nature, vol. 411, pp. 494-498 (2001). Table 2 identifies putative siRNA sequences against the human Nav1.8 coding sequence. Also shown are the target sequences, the position of each target sequence in the gene, and the percentage of guanine/cytosine in the target sequence. Table 3 identifies putative siRNA sequences against the rat Nav1.8 coding sequence. Also shown are the target sequences and the position of each target sequence in the gene.







TABLE 2







Human PN3 sIRNAs













position




Target
Target sequence
in gene
% GC














1
AATTCCCCATTGGATCCCTCG (SEQ ID NO: 12)
5
52.4



2
AAACTAACAACTTCCGTCGCT (SEQ ID NO: 13)
26
42.9


3
AACAACTTCCGTCGCTTTACT (SEQ ID NO: 14)
31
42.9


4
AACTTCCGTCGCTTTACTCCG (SEQ ID NO: 15)
34
52.4


5
AAGCAAATTGCTGCCAAGCAG (SEQ ID NO: 16)
76
47.6


6
AAATTGCTGCCAAGCAGGGAA (SEQ ID NO: 17)
80
47.6


7
AAGCAGGGAACAAAGAAAGCC (SEQ ID NO: 18)
91
47.6


8
AACAAAGAAAGCCAGAGAGAA (SEQ ID NO: 19)
99
38.1


9
AAAGAAAGCCAGAGAGAAGCA (SEQ ID NO: 20)
102
42.9


10
AAAGCCAGAGAGAAGCATAGG (SEQ ID NO: 21)
106
47.6


11
AAGCATAGGGAGCAGAAGGAC (SEQ ID NO: 22)
118
52.4


12
AAGGACCAAGAAGAGAAGCCT (SEQ ID NO: 23)
133
47.6


13
AAGAAGAGAAGCCTCGGCCCC (SEQ ID NO: 24)
140
61.9


14
AAGAGAAGCCTCGGCCCCAGC (SEQ ID NO: 25)
143
66.7


15
AAGCCTCGGCCCCAGCTGGAC (SEQ ID NO: 26)
148
71.4


16
AAAGCCTGCAACCAGCTGCCC (SEQ ID NO: 27)
172
61.9


17
AACCAGCTGCCCAAGTTCTAT (SEQ ID NO: 28)
181
47.6


18
AAGTTCTATGGTGAGCTCCCA (SEQ ID NO: 29)
193
47.6


19
AACTGATCGGGGAGCCCCTGG (SEQ ID NO: 30)
218
66.7


20
AACAAAGGGAGGACCATTTCC (SEQ ID NO: 31)
286
47.6


21
AAAGGGAGGACCATTTCCCGG (SEQ ID NO: 32)
289
57.1


22
AACCTGATCAGAAGAACGGCC (SEQ ID NO: 33)
349
52.4


23
AAGAACGGCCATCAAAGTGTC (SEQ ID NO: 34)
360
47.6


24
AACGGCCATCAAAGTGTCTGT (SEQ ID NO: 35)
363
47.6


25
AAAGTGTCTGTCCACTCGTGG (SEQ ID NO: 36)
373
52.4


26
AATTGTGTGTGCATGACCCGA (SEQ ID NO: 37)
427
47.6


27
AACTGACCTTCCAGAGAAAAT (SEQ ID NO: 38)
447
38.1


28
AAAATTGAATATGTCTTCACT (SEQ ID NO: 39)
463
23.8


29
AATTGAATATGTCTTCACTGT (SEQ ID NO: 40)
465
28.6


30
AATATGTCTTCACTGTCATTT (SEQ ID NO: 41)
470
28.6


31
AAGCCTTGATAAAGATACTGG (SEQ ID NO: 42)
500
38.1


32
AAAGATACTGGCAAGAGGATT (SEQ ID NO: 43)
510
38.1


33
AAGAGGATTTTGTCTAAATGA (SEQ ID NO: 44)
522
28.6


34
AAATGAGTTCACGTACCTGAG (SEQ ID NO: 45)
537
42.9


35
AACTGGCTGGATTTTAGCGTC (SEQ ID NO: 46)
568
47.6


36
AATAGATCTCCGTGGGATCTC (SEQ ID NO: 47)
615
47.6


37
AAAAACAGTTTCTGTGATCCC (SEQ ID NO: 48)
669
38.1


38
AAACAGTTTCTGTGATCCCAG (SEQ ID NO: 49)
671
42.9


39
AAGGTCATTGTGGGGGCCCTG (SEQ ID NO: 50)
697
61.9


40
AAGAAACTGGCTGATGTGACC (SEQ ID NO: 51)
730
47.6


41
AAACTGGCTGATGTGACCATC (SEQ ID NO: 52)
733
47.6


42
AAGTGTTTTTGCCTTGGTGGG (SEQ ID NO: 53)
771
47.6


43
AACTCTTCAAGGGCAACCTCA (SEQ ID NO: 54)
797
47.6


44
AAGGGCAACCTCAAAAATAAA (SEQ ID NO: 55)
805
33.3


45
AACCTCAAAAATAAATGTGTC (SEQ ID NO: 56)
811
28.6


46
AAAAATAAATGTGTCAAGAAT (SEQ ID NO: 57)
817
19


47
AAATAAATGTGTCAAGAATGA (SEQ ID NO: 58)
819
23.8


48
AAATGTGTCAAGAATGACATG (SEQ ID NO: 59)
823
33.3


49
AAGAATGACATGGCTGTCAAT (SEQ ID NO: 60)
832
38.1


50
AATGACATGGCTGTCAATGAG (SEQ ID NO: 61)
835
42.9


51
AATGAGACAACCAACTACTCA (SEQ ID NO: 62)
850
38.1


52
AACCAACTACTCATCTCACAG (SEQ ID NO: 63)
858
42.9


53
AACTACTCATCTCACAGAAAA (SEQ ID NO: 64)
862
33.3


54
AAAACCAGATATCTACATAAA (SEQ ID NO: 65)
879
23.8


55
AACCAGATATCTACATAAATA (SEQ ID NO: 66)
881
23.8


56
AAATAAGCGAGGCACTTCTGA (SEQ ID NO: 67)
897
42.9


57
AAGCGAGGCACTTCTGACCCC (SEQ ID NO: 68)
901
61.9


58
AATGGATCTGACTCAGGCCAC (SEQ ID NO: 69)
934
52.4


59
AAAACTTCTGACAACCCGGAT (SEQ ID NO: 70)
979
42.9


60
AACTTCTGACAACCCGGATTT (SEQ ID NO: 71)
981
42.9


61
AACCCGGATTTTAACTACACC (SEQ ID NO: 72)
991
42.9


62
AACTACACCAGCTTTGATTCC (SEQ ID NO: 73)
1003
42.9


63
AACGCCTCTACCAGCAGACCC (SEQ ID NO: 74)
1076
61.9


64
AAAATCTATATGATCTTTTTT (SEQ ID NO: 75)
1111
14.3


65
AATCTATATGATCTTTTTTGT (SEQ ID NO: 76)
1113
19


66
AATCTTCCTGGGATCTTTCTA (SEQ ID NO: 77)
1140
38.1


67
AACTTGATCTTGGCTGTAGTC (SEQ ID NO: 78)
1168
42.9


68
AACCAGGCAACCACTGATGAA (SEQ ID NO: 79)
1210
47.6


69
AACCACTGATGAAATTGAAGC (SEQ ID NO: 80)
1218
38.1


70
AAATTGAAGCAAAGGAGAAGA (SEQ ID NO: 81)
1229
33.3


71
AAGCAAAGGAGAAGAAGTTCC (SEQ ID NO: 82)
1235
42.9


72
AAAGGAGAAGAAGTTCCAGGA (SEQ ID NO: 83)
1239
42.9


73
AAGAAGTTCCAGGAGGCCCTC (SEQ ID NO: 84)
1246
57.1


74
AAGTTCCAGGAGGCCCTCGAG (SEQ ID NO: 85)
1249
61.9


75
AAGGAGCAGGAGGTGCTAGCA (SEQ ID NO: 86)
1279
57.1


76
AACCTCTCTCCACTCCCACAA (SEQ ID NO: 87)
1317
52.4


77
AATGGATCACCTTTAACCTCC (SEQ ID NO: 88)
1336
42.9


78
AACCTCCAAAAATGCCAGTGA (SEQ ID NO: 89)
1350
42.9


79
AAAAATGCCAGTGAGAGAAGG (SEQ ID NO: 90)
1357
42.9


80
AAATGCCAGTGAGAGAAGGCA (SEQ ID NO: 91)
1359
47.6


81
AAGGCATAGAATAAAGCCAAG (SEQ ID NO: 92)
1374
38.1


82
AATAAAGCCAAGAGTGTCAGA (SEQ ID NO: 93)
1383
38.1


83
AAAGCCAAGAGTGTCAGAGGG (SEQ ID NO: 94)
1386
52.4


84
AAGAGTGTCAGAGGGCTCCAC (SEQ ID NO: 95)
1392
57.1


85
AAGACAACAAATCACCCCGCT (SEQ ID NO: 96)
1415
47.6


86
AACAAATCACCCCGCTCTGAT (SEQ ID NO: 97)
1420
47.6


87
AAATCACCCCGCTCTGATCCT (SEQ ID NO: 98)
1423
52.4


88
AACCAGCGCAGGATGTCTTTT (SEQ ID NO: 99)
1447
47.6


89
AAAACGCCGGGCTAGTCATGG (SEQ ID NO: 100)
1485
57.1


90
AACGCCGGGCTAGTCATGGCA (SEQ ID NO: 101)
1487
61.9


91
AAAGCCATCGGGGCTCTCTGC (SEQ ID NO: 102)
1592
61.9


92
AAGGCCCCCTCCCTAGAAGCC (SEQ ID NO: 103)
1637
66.7


93
AAGCCCTCTTCCTCAACCCAG (SEQ ID NO: 104)
1653
57.1


94
AACCCAGCAACCCTGACTCCA (SEQ ID NO: 105)
1667
57.1


95
AACCCTGACTCCAGGCATGGA (SEQ ID NO: 106)
1675
57.1


96
AAGATGAACACCAACCGCCGC (SEQ ID NO: 107)
1697
57.1


97
AACACCAACCGCCGCCCACTA (SEQ ID NO: 108)
1703
61.9


98
AACCGCCGCCCACTAGTGAGC (SEQ ID NO: 109)
1709
66.7


99
AAAAGAAGACTTTCTTGTCAG (SEQ ID NO: 110)
1772
33.3


100
AAGAAGACTTTCTTGTCAGCA (SEQ ID NO: 111)
1774
38.1


101
AAGACTTTCTTGTCAGCAGAA (SEQ ID NO: 112)
1777
38.1


102
AATACTTAGATGAACCTTTCC (SEQ ID NO: 113)
1796
33.3


103
AACCTTTCCGGGCCCAAAGGG (SEQ ID NO: 114)
1808
61.9


104
AAAGGGCAATGAGTGTTGTCA (SEQ ID NO: 115)
1823
42.9


105
AATGAGTGTTGTCAGTATCAT (SEQ ID NO: 116)
1830
33.3


106
AACCTCCGTCCTTGAGGAACT (SEQ ID NO: 117)
1851
52.4


107
AACTCGAGGAGTCTGAACAGA (SEQ ID NO: 118)
1868
47.6


108
AACAGAAGTGGCCACCCTGCT (SEQ ID NO: 119)
1883
57.1


109
AAGTGCCCACCCTGCTTGACC (SEQ ID NO: 120)
1888
61.9


110
AAGTATCTGATCTGGGATTGC (SEQ ID NO: 121)
1921
42.9


111
AAGCTCAAGACAATTCTCTTT (SEQ ID NO: 122)
1957
33.3


112
AAGACAATTCTCTTTGGGCTT (SEQ ID NO: 123)
1963
38.1


113
AATTCTCTTTGGGCTTGTGAC (SEQ ID NO: 124)
1968
42.9


114
AACACCATCTTCATGGCCATG (SEQ ID NO: 125)
2032
47.6


115
AAGCCATGCTCCAGATAGGCA (SEQ ID NO: 126)
2081
52.4


116
AACATCGTCTTTACCATATTT (SEQ ID NO: 127)
2101
28.6


117
AAATGGTCTTCAAAATCATTG (SEQ ID NO: 128)
2132
28.6


118
AAAATCATTGCCTTCGACCCA (SEQ ID NO: 129)
2143
42.9


119
AATCATTGCCTTCGACCCATA (SEQ ID NO: 130)
2145
42.9


120
AAGAAGTGGAATATCTTTGAC (SEQ ID NO: 131)
2179
33.3


121
AAGTGGAATATCTTTGACTGC (SEQ ID NO: 132)
2182
38.1


122
AATATCTTTGACTGCATCATC (SEQ ID NO: 133)
2188
33.3


123
AAGAAGGGAAGCCTGTCTGTG (SEQ ID NO: 134)
2242
52.4


124
AAGGGAAGCCTGTCTGTGCTG (SEQ ID NO: 135)
2245
57.1


125
AAGCCTGTCTGTGCTGCGGAG (SEQ ID NO: 136)
2250
61.9


126
AAGCTGGCCAAATCCTGGCCC (SEQ ID NO: 137)
2293
61.9


127
AAATCCTGGCCCACCTTAAAC (SEQ ID NO: 138)
2302
47.6


128
AAACACACTCATCAAGATCAT (SEQ ID NO: 139)
2319
33.3


129
AAGATCATCGGAAACTCAGTG (SEQ ID NO: 140)
2332
42.9


130
AAACTCAGTGGGGGCACTGGG (SEQ ID NO: 141)
2343
61.9


131
AACCTCACCATCATCCTGGCC (SEQ ID NO: 142)
2365
57.1


132
AAGCAGCTCCTAGGGGAAAAC (SEQ ID NO: 143)
2416
52.4


133
AAAACTACCGTAACAACCGAA (SEQ ID NO: 144)
2432
38.1


134
AACTACCGTAACAACCGAAAA (SEQ ID NO: 145)
2434
38.1


135
AACAACCGAAAAAATATCTCC (SEQ ID NO: 146)
2443
33.3


136
AACCGAAAAAATATCTCCGCG (SEQ ID NO: 147)
2446
42.9


137
AAAAAATATCTCCGCGCCCCA (SEQ ID NO: 148)
2451
47.6


138
AAAATATCTCCGCGCCCCATG (SEQ ID NO: 149)
2453
52.4


139
AATATCTCCGCGCCCCATGAA (SEQ ID NO: 150)
2455
52.4


140
AAGACTGGCCCCGCTGGCACA (SEQ ID NO: 151)
2474
66.7


141
AACATGTGGGCCTGCATGGAA (SEQ ID NO: 152)
2557
52.4


142
AAGTTGGCCAAAAATCCATAT (SEQ ID NO: 153)
2576
33.3


143
AAAAATCCATATGCCTCATCC (SEQ ID NO: 154)
2585
38.1


144
AAATCCATATGCCTCATCCTT (SEQ ID NO: 155)
2587
38.1


145
AACCTGGTGGTGCTTAACCTG (SEQ ID NO: 156)
2632
52.4


146
AACCTGTTCATCGCCCTGCTA (SEQ ID NO: 157)
2647
52.4


147
AACTCTTTCAGTGCTGACAAC (SEQ ID NO: 158)
2671
42.9


148
AACCTCACAGCCCCGGAGGAC (SEQ ID NO: 159)
2689
66.7


149
AACAACCTGCAGGTGGCCCTG (SEQ ID NO: 160)
2722
61.9


150
AACCTGCAGGTGGCCCTGGCA (SEQ ID NO: 161)
2725
66.7


151
AAACAGGCTCTTTGCAGCTTC (SEQ ID NO: 162)
2773
47.6


152
AAGGCAGAGCCTGAGCTGGTG (SEQ ID NO: 163)
2824
61.9


153
AAACTCCCACTCTCCAGCTCC (SEQ ID NO: 164)
2848
57.1


154
AAGGCTGAGAACCACATTGCT (SEQ ID NO: 165)
2869
47.6


155
AACCACATTGCTGCCAACACT (SEQ ID NO: 166)
2878
47.6


156
AACACTGCCAGGGGGAGCTCT (SEQ ID NO: 167)
2893
61.9


157
AAGCTCCCAGAGGCCCCAGGG (SEQ ID NO: 168)
2924
71.4


158
AATCCGACTGTGTGGGTCTCT (SEQ ID NO: 169)
2968
52.4


159
AATCTGATCTTGATGACTTGG (SEQ ID NO: 170)
3008
38.1


160
AAGATGCTCAGAGCTTCCAGC (SEQ ID NO: 171)
3044
52.4


161
AAGTGATCCCCAAAGGACAGC (SEQ ID NO: 172)
3068
52.4


162
AAAGGACAGCAGGAGCAGCTG (SEQ ID NO: 173)
3079
57.1


163
AAGTCGAGAGGTGTGGGGACC (SEQ ID NO: 174)
3104
61.9


164
AACATCTTCTGAGGACCTGGC (SEQ ID NO: 175)
3153
52.4


165
AAAGATGAGTCTGTTCCTCAG (SEQ ID NO: 176)
3196
42.9


166
AAGCTCCTCTGAGGGCAGCAC (SEQ ID NO: 177)
3243
61.9


167
AAATCCTGAGGAAGATCCCTG (SEQ ID NO: 178)
3287
47.6


168
AAGATCCCTGAGCTGGCAGAT (SEQ ID NO: 179)
3298
52.4


169
AAGAACCAGATGACTGCTTCA (SEQ ID NO: 180)
3326
42.9


170
AACCAGATGACTGCTTCACAG (SEQ ID NO: 181)
3329
47.6


171
AAGGATGCATTCGCCACTGTC (SEQ ID NO: 182)
3350
52.4


172
AAACTGGATACCACCAAGAGT (SEQ ID NO: 183)
3379
42.9


173
AAGAGTCCATGGGATGTGGGC (SEQ ID NO: 184)
3394
57.1


174
AAGACTTGCTACCGTATCGTG (SEQ ID NO: 185)
3427
47.6


175
AAGACTATTACCTGGACCAGA (SEQ ID NO: 186)
3515
42.9


176
AAGCCCACGGTGAAAGCTTTG (SEQ ID NO: 187)
3535
52.4


177
AAAGCTTTGCTGGAGTACACT (SEQ ID NO: 188)
3547
42.9


178
AAGTGGGTGGCCTATGGCTTC (SEQ ID NO: 189)
3610
57.1


179
AAAAAGTACTTCACCAATGCC (SEQ ID NO: 190)
3631
38.1


180
AAAGTACTTCACCAATGCCTG (SEQ ID NO: 191)
3633
42.9


181
AATGCCTGGTGCTGGCTGGAC (SEQ ID NO: 192)
3646
61.9


182
AATATCTCACTGATAAGTCTC (SEQ ID NO: 193)
3679
33.3


183
AAGTCTCACAGCGAAGATTCT (SEQ ID NO: 194)
3693
42.9


184
AAGATTCTGGAATATTCTGAA (SEQ ID NO: 195)
3706
28.6


185
AATATTCTGAAGTGGCTCCCA (SEQ ID NO: 196)
3716
42.9


186
AAGTGGCTCCCATCAAAGCCC (SEQ ID NO: 197)
3725
57.1


187
AAAGCCCTTCGAACCCTTCGC (SEQ ID NO: 198)
3739
57.1


188
AACCCTTCGCGCTCTGCGGCC (SEQ ID NO: 199)
3750
71.4


189
AAGGCATGCGGGTGGTGGTGG (SEQ ID NO: 200)
3794
66.7


190
AATGTCCTCCTCGTCTGCCTC (SEQ ID NO: 201)
3847
57.1


191
AACCTCTTCGCAGGGAAGTTT (SEQ ID NO: 202)
3901
47.6


192
AAGTTTTGGAGGTGCATCAAC (SEQ ID NO: 203)
3916
42.9


193
AACTATACCGATGGAGAGTTT (SEQ ID NO: 204)
3934
38.1


194
AATAACAAGTCTGACTGCAAG (SEQ ID NO: 205)
3979
38.1


195
AACAAGTCTGACTGCAAGATT (SEQ ID NO: 206)
3982
38.1


196
AAGTCTGACTGCAAGATTCAA (SEQ ID NO: 207)
3985
38.1


197
AAGATTCAAAACTCCACTGGC (SEQ ID NO: 208)
3997
42.9


198
AAAACTCCACTGGCAGCTTCT (SEQ ID NO: 209)
4004
47.6


199
AACTCCACTGGCAGCTTCTTC (SEQ ID NO: 210)
4006
52.4


200
AATGTGAAAGTCAACTTTGAT (SEQ ID NO: 211)
4033
28.6


201
AAAGTCAACTTTGATAATGTT (SEQ ID NO: 212)
4039
23.8


202
AACTTTGATAATGTTGCAATG (SEQ ID NO: 213)
4045
28.6


203
AATGTTGCAATGGGTTACCTT (SEQ ID NO: 214)
4054
38.1


204
AATGGGTTACCTTGCACTTCT (SEQ ID NO: 215)
4062
42.9


205
AACCTTTAAAGGCTGGATGGA (SEQ ID NO: 216)
4092
42.9


206
AAAGGCTGGATGGACATTATG (SEQ ID NO: 217)
4099
42.9


207
AACATGCAACCCAAGTGGGAG (SEQ ID NO: 218)
4147
52.4


208
AACCCAAGTGGGAGGACAACG (SEQ ID NO: 219)
4154
57.1


209
AAGTGGGAGGACAACGTGTAC (SEQ ID NO: 220)
4159
52.4


210
AACGTGTACATGTATTTGTAC (SEQ ID NO: 221)
4171
33.3


211
AATCTCTTTGTTGGGGTCATA (SEQ ID NO: 222)
4231
38.1


212
AATTGACAACTTCAATCAACA (SEQ ID NO: 223)
4251
28.6


213
AACTTCAATCAACAGAAAAAA (SEQ ID NO: 224)
4258
23.8


214
AATCAACAGAAAAAAAAGTTA (SEQ ID NO: 225)
4264
19


215
AACAGAAAAAAAAGTTAGGGG (SEQ ID NO: 226)
4268
33.3


216
AAAAAAAAGTTAGGGGGCCAG (SEQ ID NO: 227)
4273
42.9


217
AAAAAAGTTAGGGGGCCAGGA (SEQ ID NO: 228)
4275
47.6


218
AAAAGTTAGGGGGCCAGGACA (SEQ ID NO: 229)
4277
52.4


219
AAGTTAGGGGGCCAGGACATC (SEQ ID NO: 230)
4279
57.1


220
AAGAAATACTACAATGCCATG (SEQ ID NO: 231)
4318
33.3


221
AAATACTACAATGCCATGAAG (SEQ ID NO: 232)
4321
33.3


222
AATGCCATGAAGAAGTTGGGC (SEQ ID NO: 233)
4330
47.6


223
AAGAAGTTGGGCTCCAAGAAG (SEQ ID NO: 234)
4339
47.6


224
AAGTTGGGCTCCAAGAAGCCC (SEQ ID NO: 235)
4342
57.1


225
AAGAAGCCCCAGAAGCCCATC (SEQ ID NO: 236)
4354
57.1


226
AAGCCCCAGAAGCCCATCCCA (SEQ ID NO: 237)
4357
61.9


227
AAGCCCATCCCACGGCCCCTG (SEQ ID NO: 238)
4366
71.4


228
AACAAGTTCCAGGGTTTTGTC (SEQ ID NO: 239)
4387
42.9


229
AAGTTCCAGGGTTTTGTCTTT (SEQ ID NO: 240)
4390
38.1


230
AAGCTTTTGACATCACCATCA (SEQ ID NO: 241)
4427
38.1


231
AACATGATCACCATGATGGTG (SEQ ID NO: 242)
4465
42.9


232
AAAGTGAAGAAAAGACGAAAA (SEQ ID NO: 243)
4499
28.6


233
AAGAAAAGACGAAAATTCTGG (SEQ ID NO: 244)
4505
33.3


234
AAAAGACGAAAATTCTGGGCA (SEQ ID NO: 245)
4508
38.1


235
AAGACGAAAATTCTGGGCAAA (SEQ ID NO: 246)
4510
38.1


236
AAAATTCTGGGCAAAATCAAC (SEQ ID NO: 247)
4516
33.3


237
AATTCTGGGCAAAATCAACCA (SEQ ID NO: 248)
4518
38.1


238
AAAATCAACCAGTTCTTTGTG (SEQ ID NO: 249)
4528
33.3


239
AATCAACCAGTTCTTTGTGGC (SEQ ID NO: 250)
4530
42.9


240
AACCAGTTCTTTGTGGCCGTC (SEQ ID NO: 251)
4534
52.4


241
AATGTGTCATGAAGATGTTCG (SEQ ID NO: 252)
4565
38.1


242
AAGATGTTCGCTTTGAGGCAG (SEQ ID NO: 253)
4576
47.6


243
AAATGGCTGGAATGTGTTTGA (SEQ ID NO: 254)
4608
38.1


244
AATGTGTTTGACTTCATTGTG (SEQ ID NO: 255)
4618
33.3


245
AATTCTTAAGTCACTTCAAAG (SEQ ID NO: 256)
4674
28.6


246
AAGTCACTTCAAAGTTACTTC (SEQ ID NO: 257)
4681
33.3


247
AAAGTTACTTCTCCCCAACGC (SEQ ID NO: 258)
4691
47.6


248
AACGCTCTTCAGAGTCATCCG (SEQ ID NO: 259)
4707
52.4


249
AATTGGCCGCATCCTCAGACT (SEQ ID NO: 260)
4737
52.4


250
AAGGGGATCCGCACACTGCTC (SEQ ID NO: 261)
4771
61.9


251
AACATCGGGCTGTTGCTATTC (SEQ ID NO: 262)
4825
47.6


252
AACTTCCAGACCTTCGCCAAC (SEQ ID NO: 263)
4927
52.4


253
AACAGCATGCTGTGCCTCTTC (SEQ ID NO: 264)
4945
52.4


254
AACACAGGGCCCCCCTACTGT (SEQ ID NO: 265)
5014
61.9


255
AATCTGCCCAACAGCAATGGC (SEQ ID NO: 266)
5041
52.4


256
AACAGCAATGGCACCAGAGGG (SEQ ID NO: 267)
5050
57.1


257
AATGGCACCAGAGGGGACTGT (SEQ ID NO: 268)
5056
57.1


258
AACATGTACATTGCAGTGATT (SEQ ID NO: 269)
5143
33.3


259
AACTTCAATGTGGCCACGGAG (SEQ ID NO: 270)
5170
52.4


260
AATGTGGCCACGGAGGAGAGC (SEQ ID NO: 271)
5176
61.9


261
AAGTTTGACCCAGAGGCCACT (SEQ ID NO: 272)
5248
52.4


262
AATCCCAAAACCCAATCGAAA (SEQ ID NO: 273)
5328
38.1


263
AAAACCCAATCGAAATATACT (SEQ ID NO: 274)
5334
28.6


264
AACCCAATCGAAATATACTGA (SEQ ID NO: 275)
5336
33.3


265
AATCGAAATATACTGATCCAG (SEQ ID NO: 276)
5341
33.3


266
AAATATACTGATCCAGATGGA (SEQ ID NO: 277)
5346
33.3


267
AAGATCCACTGCTTGGACATC (SEQ ID NO: 278)
5389
47.6


268
AAGAATGTCCTAGGAGAATCC (SEQ ID NO: 279)
5425
42.9


269
AATGTCCTAGGAGAATCCGGG (SEQ ID NO: 280)
5428
52.4


270
AATCCGGGGAGTTGGATTCTC (SEQ ID NO: 281)
5441
52.4


271
AAGGCAAATATGGAGGAGAAG (SEQ ID NO: 282)
5464
42.9


272
AAATATGGAGGAGAAGTTTAT (SEQ ID NO: 283)
5469
28.6


273
AAGTTTATGGCAACTAATCTT (SEQ ID NO: 284)
5482
28.6


274
AACTAATCTTTCAAAATCATC (SEQ ID NO: 285)
5493
23.8


275
AATCTTTCAAAATCATCCTAT (SEQ ID NO: 286)
5497
23.8


276
AAAATCATCCTATGAACCAAT (SEQ ID NO: 287)
5505
28.6


277
AATCATCCTATGAACCAATAG (SEQ ID NO: 288)
5507
33.3


278
AACCAATAGCAACCACTCTCC (SEQ ID NO: 289)
5519
47.6


279
AATAGCAACCACTCTCCGATG (SEQ ID NO: 290)
5523
47.6


280
AACCACTCTCCGATGGAAGCA (SEQ ID NO: 291)
5529
52.4


281
AAGCAAGAAGACATTTCAGCC (SEQ ID NO: 292)
5545
42.9


282
AAGAAGACATTTCAGCCACTG (SEQ ID NO: 293)
5549
42.9


283
AAGACATTTCAGCCACTGTCA (SEQ ID NO: 294)
5552
42.9


284
AAAAGGCCTATCGGAGCTATG (SEQ ID NO: 295)
5576
47.6


285
AAGGCCTATCGGAGCTATGTG (SEQ ID NO: 296)
5578
52.4


286
AACACCCCATGTGTGCCCAGA (SEQ ID NO: 297)
5623
57.1


287
AAGGTTTTGTTGCATTCACAG (SEQ ID NO: 298)
5675
38.1


288
AAATGAAAATTGTGTACTCCC (SEQ ID NO: 299)
5697
33.3


289
AAAATTGTGTACTCCCAGACA (SEQ ID NO: 300)
5702
38.1


290
AATTGTGTACTCCCAGACAAA (SEQ ID NO: 301)
5704
38.1


291
AAATCTGAAACTGCTTCTGCC (SEQ ID NO: 302)
5722
42.9


292
AAACTGCTTCTGCCACATCAT (SEQ ID NO: 303)
5729
42.9


293
AACATGAGGACATCTAGCTCA (SEQ ID NO: 304)
5797
42.9


294
AATACAAAATGAAGATGAAGC (SEQ ID NO: 305)
5817
28.6


295
AAAATGAAGATGAAGCCACCA (SEQ ID NO: 306)
5822
38.1


296
AATGAAGATGAAGCCACCAGT (SEQ ID NO: 307)
5824
42.9


297
AAGATGAAGCCACCAGTATGG (SEQ ID NO: 308)
5828
47.6


298
AAGCCACCAGTATGGAGCTGA (SEQ ID NO: 309)
5834
52.4
















TABLE 3







Rat PN3 siRNA's












posi-





tion


Tar-

in


get
Target sequence
gene













1
AACTACCAATTTCAGACGGTT (SEQ ID NO: 310)
27



2
AATTTCAGACGGTTCACTCCA (SEQ ID NO: 311)
34


3
AAGCAGATTGCTGCTCACCGC (SEQ ID NO: 312)
76


4
AAGAAGGCCAGAACCAAGCAC (SEQ ID NO: 313)
103


5
AAGGCCAGAACCAAGCACAGA (SEQ ID NO: 314)
106


6
AACCAAGCACAGAGGACAGGA (SEQ ID NO: 315)
114


7
AAGCACAGAGGACAGGAGGAC (SEQ ID NO: 316)
118


8
AAGGGCGAGAAGCCCAGGCCT (SEQ ID NO: 317)
139


9
AAGCCCAGGCCTCAGCTGGAC (SEQ ID NO: 318)
148


10
AAAGCCTGTAACCAGCTGCCC (SEQ ID NO: 319)
172


11
AACCAGCTGCCCAAGTTCTAT (SEQ ID NO: 320)
181


12
AAGTTCTATGGTGAGCTCCCA (SEQ ID NO: 321)
193


13
AACTGGTCGGGGAGCCCCTGG (SEQ ID NO: 322)
218


14
AATAAAAGCAGGACCATTTCC (SEQ ID NO: 323)
286


15
AAAAGCAGGACCATTTCCAGA (SEQ ID NO: 324)
289


16
AAGCAGGACCATTTCCAGATT (SEQ ID NO: 325)
291


17
AACCTGATCAGAAGAACAGCC (SEQ ID NO: 326)
349


18
AAGAACAGCCATCAAAGTGTC (SEQ ID NO: 327)
360


19
AACAGCCATCAAAGTGTCTGT (SEQ ID NO: 328)
363


20
AAAGTGTCTGTCCATTCCTGG (SEQ ID NO: 329)
373


21
AACTGCGTGTGCATGACCCGA (SEQ ID NO: 330)
427


22
AACTGATCTTCCAGAGAAAGT (SEQ ID NO: 331)
447


23
AAAGTCGAGTACGTCTTCACT (SEQ ID NO: 332)
463


24
AAGATACTGGCAAGAGGGTTT (SEQ ID NO: 333)
511


25
AAGAGGGTTTTGTCTAAATGA (SEQ ID NO: 334)
522


26
AAATGAGTTCACTTATCTTCG (SEQ ID NO: 335)
537


27
AACTGGCTGGACTTCAGTGTC (SEQ ID NO: 336)
568


28
AATCTCAGGCCTGCGGACATT (SEQ ID NO: 337)
630


29
AAAACTGTTTCTGTGATCCCA (SEQ ID NO: 338)
670


30
AACTGTTTCTGTGATCCCAGG (SEQ ID NO: 339)
672


31
AAGGTCATCGTGGGAGCCCTG (SEQ ID NO: 340)
697


32
AAGCTGGCCGACGTGACTATC (SEQ ID NO: 341)
733


33
AAGGGGAACCTTAAGAACAAA (SEQ ID NO: 342)
805


34
AACCTTAAGAACAAATGCATC (SEQ ID NO: 343)
811


35
AAGAACAAATGCATCAGGAAC (SEQ ID NO: 344)
817


36
AACAAATGCATCAGGAACGGA (SEQ ID NO: 345)
820


37
AAATGCATCAGGAACGGAACA (SEQ ID NO: 346)
823


38
AACGGAACAGATCCCCACAAG (SEQ ID NO: 347)
835


39
AACAGATCCCCACAAGGCTGA (SEQ ID NO: 348)
840


40
AAGGCTGACAACCTCTCATCT (SEQ ID NO: 349)
853


41
AACCTCTCATCTGAAATGGCA (SEQ ID NO: 350)
862


42
AAATGGCAGAATACATCTTCA (SEQ ID NO: 351)
875


43
AATACATCTTCATCAAGCCTG (SEQ ID NO: 352)
884


44
AAGCCTGGTACTACGGATCCC (SEQ ID NO: 353)
898


45
AATGGGTCTGATGCTGGTCAC (SEQ ID NO: 354)
931


46
AAAACTCCTGACAACCCGGAT (SEQ ID NO: 355)
976


47
AACTCCTGACAACCCGGATTT (SEQ ID NO: 356)
978


48
AACCCGGATTTTAACTACACC (SEQ ID NO: 357)
988


49
AACTACACCAGCTTTGATTCC (SEQ ID NO: 358)
1000


50
AAAATGTACATGGTCTTTTTC (SEQ ID NO: 359)
1108


51
AATGTACATGGTCTTTTTCGT (SEQ ID NO: 360)
1110


52
AATTTGATCTTGGCCGTGGTC (SEQ ID NO: 361)
1165


53
AAGAGCAGAGCCAGGCAACAA (SEQ ID NO: 362)
1199


54
AACAATTGCAGAAATCGAAGC (SEQ ID NO: 363)
1215


55
AATTGCAGAAATCGAAGCCAA (SEQ ID NO: 364)
1218


56
AAATCGAAGCCAAGGAAAAAA (SEQ ID NO: 365)
1226


57
AAGCCAAGGAAAAAAAGTTCC (SEQ ID NO: 366)
1232


58
AAGGAAAAAAAGTTCCAGGAA (SEQ ID NO: 367)
1237


59
AAAAAAAGTTCCAGGAAGCCC (SEQ ID NO: 368)
1241


60
AAAAAGTTCCAGGAAGCCCTT (SEQ ID NO: 369)
1243


61
AAAGTTCCAGGAAGCCCTTGA (SEQ ID NO: 370)
1245


62
AAGCCCTTGAGGTGCTGCAGA (SEQ ID NO: 371)
1256


63
AAGGAACAGGAGGTGCTGGCA (SEQ ID NO: 372)
1276


64
AACAGGAGGTGCTGGCAGCCC (SEQ ID NO: 373)
1280


65
AAAAACGCCAATGAGAGAAGA (SEQ ID NO: 374)
1354


66
AAACGCCAATGAGAGAAGACC (SEQ ID NO: 375)
1356


67
AATGAGAGAAGACCCAGGGTG (SEQ ID NO: 376)
1363


68
AAGACCCAGGGTGAAATCAAG (SEQ ID NO: 377)
1371


69
AAATCAAGGGTGTCAGAGGGC (SEQ ID NO: 378)
1384


70
AAGGGTGTCAGAGGGCTCCAC (SEQ ID NO: 379)
1389


71
AACAGGTCACCCCAATCTGAC (SEQ ID NO: 380)
1417


72
AATCTGACCCTTACAACCAGC (SEQ ID NO: 381)
1430


73
AACCAGCGCAGGATGTCTTTC (SEQ ID NO: 382)
1444


74
AAGACGCAGGGCTAGCCACGG (SEQ ID NO: 383)
1482


75
AAGACATCTCATTTCCTGACG (SEQ ID NO: 384)
1532


76
AAAGCCGTCGAGGTTCCATAT (SEQ ID NO: 385)
1589


77
AACCCTGGCCGTAGACATGGA (SEQ ID NO: 386)
1672


78
AAGAGGGACAGCTCGGAGTGC (SEQ ID NO: 387)
1694


79
AAGGCCCGGCACTCGACACTA (SEQ ID NO: 388)
1745


80
AAGAGCTTCCTGTCTGCGGGC (SEQ ID NO: 389)
1774


81
AACGAACCTTTCCGAGCACAG (SEQ ID NO: 390)
1801


82
AACCTTTCCGAGCACAGAGGG (SEQ ID NO: 391)
1805


83
AAGAGTCTAAGCTGAAGTGCC (SEQ ID NO: 392)
1871


84
AAGCTGAAGTGCCCACCCTGC (SEQ ID NO: 393)
1879


85
AAGTGCCCACCCTGCTTGATC (SEQ ID NO: 394)
1885


86
AAGTATCTGATCTGGGAGTGC (SEQ ID NO: 395)
1918


87
AAGTGGAGGAAGTTCAAGATG (SEQ ID NO: 396)
1945


88
AAGTTCAAGATGGCGCTGTTC (SEQ ID NO: 397)
1954


89
AAGATGGCGCTGTTCGAGCTG (SEQ ID NO: 398)
1960


90
AACACCGTCTTCATGGCCATG (SEQ ID NO: 399)
2029


91
AAGCCGGCAACATTGTCTTCA (SEQ ID NO: 400)
2090


92
AACATTGTCTTCACCGTGTTT (SEQ ID NO: 401)
2098


93
AATGGAGATGGCCTTCAAGAT (SEQ ID NO: 402)
2124


94
AAGATCATTGCCTTCGACCCC (SEQ ID NO: 403)
2140


95
AAGAAGTGGAATATCTTCGAC (SEQ ID NO: 404)
2176


96
AAGTGGAATATCTTCGACTGT (SEQ ID NO: 405)
2179


97
AATATCTTCGACTGTGTCATC (SEQ ID NO: 406)
2185


98
AAGAAGGGCAGCCTGTCTGTG (SEQ ID NO: 407)
2239


99
AAGGGCAGCCTGTCTGTGCTC (SEQ ID NO: 408)
2242


100
AAGCTGGCCAAGTCCTGGCCC (SEQ ID NO: 409)
2290


101
AAGTCCTGGCCCACCCTGAAC (SEQ ID NO: 410)
2299


102
AACACCCTCATCAAGATCATC (SEQ ID NO: 411)
2317


103
AAGATCATCGGGAACTCCGTG (SEQ ID NO: 412)
2329


104
AACTCCGTGGGGGCCCTGGGC (SEQ ID NO: 413)
2341


105
AACCTGACCTTTATCCTGGCC (SEQ ID NO: 414)
2362


106
AAAGCAGCTTCTCTCAGAGGA (SEQ ID NO: 415)
2412


107
AAGGACGGCGTCTCCGTGTGG (SEQ ID NO: 416)
2446


108
AACGGCGAGAAGCTCCGCTGG (SEQ ID NO: 417)
2467


109
AAGCTCCGCTGGCACATGTGT (SEQ ID NO: 418)
2476


110
AATCCTCTGCGGGGAGTGGAT (SEQ ID NO: 419)
2529


111
AACATGTGGGTCTGCATGGAG (SEQ ID NO: 420)
2554


112
AAATCCATCTGCCTCATCCTC (SEQ ID NO: 421)
2584


113
AACCTAGTGGTGCTCAACCTT (SEQ ID NO: 422)
2629


114
AACCTTTTCATCGCTTTACTG (SEQ ID NO: 423)
2644


115
AACTCCTTCAGCGCGGACAAC (SEQ ID NO: 424)
2668


116
AACCTCACGGCTCCAGAGGAT (SEQ ID NO: 425)
2686


117
AACAACTTGCAGTTAGCACTG (SEQ ID NO: 426)
2719


118
AACTTGCAGTTAGCACTGGCC (SEQ ID NO: 427)
2722


119
AAGGTGGAGACCCAGCTGGGC (SEQ ID NO: 428)
2821


120
AAGCCCCCACTCACCAGCTCA (SEQ ID NO: 429)
2845


121
AAGAACCACATTGCCACTGAT (SEQ ID NO: 430)
2872


122
AACCACATTGCCACTGATGCT (SEQ ID NO: 431)
2875


123
AACCTGACAAAGCCAGCTCTC (SEQ ID NO: 432)
2914


124
AAAGCCAGCTCTCAGTAGCCC (SEQ ID NO: 433)
2922


125
AAGGAGAACCACGGGGACTTC (SEQ ID NO: 434)
2944


126
AACCACGGGGACTTCATCACT (SEQ ID NO: 435)
2950


127
AACGTGTGGGTCTCTGTGCCC (SEQ ID NO: 436)
2977


128
AATCTGACCTCGACGAGCTCG (SEQ ID NO: 437)
3011


129
AAGATATGGAGCAGGCTTCGC (SEQ ID NO: 438)
3035


130
AAGAGGACCCCAAGGGACAGC (SEQ ID NO: 439)
3071


131
AAGGGACAGCAGGAGCAGTTG (SEQ ID NO: 440)
3082


132
AAGTCCAAAAGTGTGAAAACC (SEQ ID NO: 441)
3107


133
AAAAGTGTGAAAACCACCAGG (SEQ ID NO: 442)
3113


134
AAGTGTGAAAACCACCAGGCA (SEQ ID NO: 443)
3115


135
AAAACCACCAGGCAGCCAGAA (SEQ ID NO: 444)
3122


136
AACCACCAGGCAGCCAGAAGC (SEQ ID NO: 445)
3124


137
AAGCCCAGCCTCCATGATGTC (SEQ ID NO: 446)
3141


138
AAGAGGAAGGATAGCCCTCAG (SEQ ID NO: 447)
3199


139
AAGGATAGCCCTCAGGTCCCT (SEQ ID NO: 448)
3205


140
AAATCCTGAGGAAGATCCCCG (SEQ ID NO: 449)
3290


141
AAGATCCCCGAGCTGGCAGAT (SEQ ID NO: 450)
3301


142
AAGGCTGCACTCGCCGCTGTC (SEQ ID NO: 451)
3353


143
AACGTGAATACTAGCAAGTCT (SEQ ID NO: 452)
3382


144
AATACTAGCAAGTCTCCTTGG (SEQ ID NO: 453)
3388


145
AAGTCTCCTTGGGCCACAGGC (SEQ ID NO: 454)
3397


146
AAGACCTGCTACCGCATCGTG (SEQ ID NO: 455)
3430


147
AACTACCTGGAAGAGAAACCC (SEQ ID NO: 456)
3523


148
AAGAGAAACCCCGAGTGAAGT (SEQ ID NO: 457)
3533


149
AAACCCCGAGTGAAGTCCGTG (SEQ ID NO: 458)
3538


150
AAGTCCGTGCTGGAGTACACT (SEQ ID NO: 459)
3550


151
AAGTGGGTAGCCTATGGCTTC (SEQ ID NO: 460)
3613


152
AAAAAGTATTTCACCAATGCC (SEQ ID NO: 461)
3634


153
AAAGTATTTCACCAATGCCTG (SEQ ID NO: 462)
3636


154
AATGCCTGGTGCTGGCTGGAC (SEQ ID NO: 463)
3649


155
AACATCTCCCTGACAAGCCTC (SEQ ID NO: 464)
3682


156
AAGCCTCATAGCGAAGATCCT (SEQ ID NO: 465)
3696


157
AAGATCCTTGAGTATTCCGAC (SEQ ID NO: 466)
3709


158
AAAGCCCTTCGGACTCTCCGT (SEQ ID NO: 467)
3742


159
AAGGCATGAGGGTAGTGGTGG (SEQ ID NO: 468)
3797


160
AACGTCCTCCTCGTCTGCCTC (SEQ ID NO: 469)
3850


161
AACCTCTTCGCCGGGAAATTT (SEQ ID NO: 470)
3904


162
AAATTTTCGAAGTGCGTCGAC (SEQ ID NO: 471)
3919


163
AAGTGCGTCGACACCAGAAAT (SEQ ID NO: 472)
3928


164
AAATAACCCATTTTCCAACGT (SEQ ID NO: 473)
3945


165
AACCCATTTTCCAACGTGAAT (SEQ ID NO: 474)
3949


166
AACGTGAATTCGACGATGGTG (SEQ ID NO: 475)
3961


167
AATTCGACGATGGTGAATAAC (SEQ ID NO: 476)
3967


168
AATAACAAGTCCGAGTGTCAC (SEQ ID NO: 477)
3982


169
AACAAGTCCGAGTGTCACAAT (SEQ ID NO: 478)
3985


170
AAGTCCGAGTGTCACAATCAA (SEQ ID NO: 479)
3988


171
AATCAAAACAGCACCGGCCAC (SEQ ID NO: 480)
4003


172
AAAACAGCACCGGCCACTTCT (SEQ ID NO: 481)
4007


173
AACAGCACCGGCCACTTCTTC (SEQ ID NO: 482)
4009


174
AACGTCAAAGTCAACTTCGAC (SEQ ID NO: 483)
4036


175
AAAGTCAACTTCGACAACGTC (SEQ ID NO: 484)
4042


176
AACTTCGACAACGTCGCTATG (SEQ ID NO: 485)
4048


177
AACGTCGCTATGGGCTACCTC (SEQ ID NO: 486)
4057


178
AACCTTCAAAGGCTGGATGGA (SEQ ID NO: 487)
4095


179
AAAGGCTGGATGGACATAATG (SEQ ID NO: 488)
4102


180
AATGTATGCAGCTGTTGATTC (SEQ ID NO: 489)
4119


181
AACAGTCAGCCTAACTGGGAG (SEQ ID NO: 490)
4150


182
AACTGGGAGAACAACTTGTAC (SEQ ID NO: 491)
4162


183
AACAACTTGTACATGTACCTG (SEQ ID NO: 492)
4171


184
AACTTGTACATGTACCTGTAC (SEQ ID NO: 493)
4174


185
AATCTCTTTGTTGGGGTCATA (SEQ ID NO: 494)
4234


186
AATCGACAACTTCAACCAACA (SEQ ID NO: 495)
4254


187
AACTTCAACCAACAGAAAAAA (SEQ ID NO: 496)
4261


188
AACCAACAGAAAAAAAAGCTA (SEQ ID NO: 497)
4267


189
AACAGAAAAAAAAGCTAGGAG (SEQ ID NO: 498)
4271


190
AAAAAAAAGCTAGGAGGCCAG (SEQ ID NO: 499)
4276


191
AAAAAAGCTAGGAGGCCAGGA (SEQ ID NO: 500)
4278


192
AAAAGCTAGGAGGCCAGGACA (SEQ ID NO: 501)
4280


193
AAGCTAGGAGGCCAGGACATC (SEQ ID NO: 502)
4282


194
AAGAGCAGAAGAAGTACTACA (SEQ ID NO: 503)
4313


195
AAGAAGTACTACAATGCCATG (SEQ ID NO: 504)
4321


196
AAGTACTACAATGCCATGAAG (SEQ ID NO: 505)
4324


197
AATGCCATGAAGAAGCTGGGC (SEQ ID NO: 506)
4333


198
AAGAAGCTGGGCTCCAAGAAA (SEQ ID NO: 507)
4342


199
AAGCTGGGCTCCAAGAAACCC (SEQ ID NO: 508)
4345


200
AAGAAACCCCAGAAGCCCATC (SEQ ID NO: 509)
4357


201
AAACCCCAGAAGCCCATCCCA (SEQ ID NO: 510)
4360


202
AAGCCCATCCCACGGCCCCTG (SEQ ID NO: 511)
4369


203
AATAAGTACCAAGGCTTCGTG (SEQ ID NO: 512)
4390


204
AAGTACCAAGGCTTCGTGTTT (SEQ ID NO: 513)
4393


205
AAGGCTTCGTGTTTGACATCG (SEQ ID NO: 514)
4400


206
AAGCCTTTGACATCATCATCA (SEQ ID NO: 515)
4430


207
AACATGATCACCATGATGGTG (SEQ ID NO: 516)
4468


208
AAGACGAAGGTTCTGGGCAGA (SEQ ID NO: 517)
4513


209
AAGGTTCTGGGCAGAATCAAC (SEQ ID NO: 518)
4519


210
AATCAACCAGTTCTTTGTGGC (SEQ ID NO: 519)
4533


211
AACCAGTTCTTTGTGGCCGTC (SEQ ID NO: 520)
4537


212
AAGATGTTCGCCCTGCGACAG (SEQ ID NO: 521)
4579


213
AACGGCTGGAACGTGTTCGAC (SEQ ID NO: 522)
4612


214
AACGTGTTCGACTTCATAGTG (SEQ ID NO: 523)
4621


215
AATCCTTAAGTCACTGGAAAA (SEQ ID NO: 524)
4677


216
AAGTCACTGGAAAACTACTTC (SEQ ID NO: 525)
4684


217
AAAACTACTTCTCCCCGACGC (SEQ ID NO: 526)
4694


218
AACTACTTCTCCCCGACGCTC (SEQ ID NO: 527)
4696


219
AAGGGGATTCGCACGCTGCTC (SEQ ID NO: 528)
4774


220
AACATCGGCCTCCTCCTCTTC (SEQ ID NO: 529)
4828


221
AACGTCGTGGACGAGGCCGGC (SEQ ID NO: 530)
4894


222
AACTTCAAGACCTTTGGCAAC (SEQ ID NO: 531)
4930


223
AAGACCTTTGGCAACAGCATG (SEQ ID NO: 532)
4936


224
AACAGCATGCTGTGCCTGTTC (SEQ ID NO: 533)
4948


225
AACACGGGGCCTCCCTACTGC (SEQ ID NO: 534)
5017


226
AACCTGCCCAACAGCAACGGC (SEQ ID NO: 535)
5044


227
AACAGCAACGGCTCCCGGGGG (SEQ ID NO: 536)
5053


228
AACGGCTCCCGGGGGAACTGC (SEQ ID NO: 537)
5059


229
AACTGCGGGAGCCCGGCGGTG (SEQ ID NO: 538)
5074


230
AACATGTACATCGCAGTGATT (SEQ ID NO: 539)
5146


231
AACTTCAACGTGGCCACCGAG (SEQ ID NO: 540)
5173


232
AACGTGGCCACCGAGGAGAGC (SEQ ID NO: 541)
5179


233
AAGTTCGACCCGGAGGCCACC (SEQ ID NO: 542)
5251


234
AATCCCCAAACCCAACCAGAA (SEQ ID NO: 543)
5331


235
AAACCCAACCAGAATATATTA (SEQ ID NO: 544)
5338


236
AACCAGAATATATTAATCCAG (SEQ ID NO: 545)
5344


237
AATATATTAATCCAGATGGAC (SEQ ID NO: 546)
5350


238
AATCCAGATGGACCTGCCGTT (SEQ ID NO: 547)
5358


239
AAGATCCACTGTCTGGACATC (SEQ ID NO: 548)
5392


240
AAAGAACGTCTTGGGAGAATC (SEQ ID NO: 549)
5427


241
AACGTCTTGGGAGAATCCGGG (SEQ ID NO: 550)
5431


242
AATCCGGGGAGTTGGACTCCC (SEQ ID NO: 551)
5444


243
AAGACCAATATGGAAGAGAAG (SEQ ID NO: 552)
5467


244
AATATGGAAGAGAAGTTTATG (SEQ ID NO: 553)
5473


245
AAGAGAAGTTTATGGCGACCA (SEQ ID NO: 554)
5480


246
AAGTTTATGGCGACCAATCTC (SEQ ID NO: 555)
5485


247
AATCTCTCCAAAGCATCCTAT (SEQ ID NO: 556)
5500


248
AAAGCATCCTATGAACCAATA (SEQ ID NO: 557)
5509


249
AACCAATAGCCACCACCCTCC (SEQ ID NO: 558)
5522


250
AATAGCCACCACCCTCCGGTG (SEQ ID NO: 559)
5526


251
AAGCAGGAAGACCTCTCAGCC (SEQ ID NO: 560)
5548


252
AAGACCTCTCAGCCACAGTCA (SEQ ID NO: 561)
5555


253
AAAAGGCCTACCGGAGCTACA (SEQ ID NO: 562)
5579


254
AAGGCCTACCGGAGCTACATG (SEQ ID NO: 563)
5581


255
AACACCCTGCATGTGCCCAGG (SEQ ID NO: 564)
5626


256
AAGGCTACGTTACATTCATGG (SEQ ID NO: 565)
5678


257
AAACAGTGGACTCCCGGACAA (SEQ ID NO: 566)
5700


258
AAATCAGAAACTGCCTCTGCT (SEQ ID NO: 567)
5719


259
AAACTGCCTCTGCTACGTCTT (SEQ ID NO: 568)
5726


260
AACATTAACCCATCTAGCTCA (SEQ ID NO: 569)
5794


261
AACCCATCTAGCTCAATGCAA (SEQ ID NO: 570)
5800


262
AATGCAAAATGAAGATGAGGT (SEQ ID NO: 571)
5814


263
AAAATGAAGATGAGGTCGCTG (SEQ ID NO: 572)
5819


264
AATGAAGATGAGGTCGCTGCT (SEQ ID NO: 573)
5821


265
AAGATGAGGTCGCTGCTAAGG (SEQ ID NO: 574)
5825


266
AAGGAAGGAAACAGCCCTGGA (SEQ ID NO: 575)
5842


267
AAGGAAACAGCCCTGGACCTC (SEQ ID NO: 576)
5846


268
AAACAGCCCTGGACCTCAGTG (SEQ ID NO: 577)
5850









Of the above siRNA sequences, five were selected for testing their ability to knock-down Nav1.8 expression and function in vitro. The five siRNAs were selected so as to cover different regions of the entire 5874 nucleotide Nav1.8 coding sequence. The five siRNA sequences, including the nucleotide position at which each sequence is located within the genome, are shown below in Table 4:










TABLE 4







Nuc.



sIRNA
Sequence
Pos.


















siRNA 1
AAAAGCAGGACCAUUUCCAGA (SEQ ID NO: 1)
289



 


siRNA 2
AAAGUGUCUGUCCAUUCCUGG (SEQ ID NO: 2)
373


 


siRNA 3
AACUACACCAGCUUUGAUUCC (SEQ ID NO: 3)
1000


 


siRNA 4
AAAUCCAUCUGCCUCAUCCUC (SEQ ID NO: 4)
2584


 


siRNA 5
AAUAAGUACCAAGGCUUCGUG (SEQ ID NO: 5)
4390









Example 2
The above five selected siRNA sequences, SEQ ID NOs: 1-5, were synthesized by Qiagen Inc., Valencia, Calif. We then cloned the Nav1.8 cDNA into a pcDNA3.1 mammalian expression plasmid (Invitrogen, Carlsbad, Calif.) to generate a pcDNA-Nav1.8 control expression plasmid. Upon transfection of the control plasmid into HEK293 cells (Microbix Biosystems, Inc., Ontario, Canada M8Z3A8), the cells exhibited high levels of Nav1.8 RNA and protein expression. Nav1.8 RNA expression was detected by Taqman® quantitative RT-PCR (Applied Biosystems, Foster City, Calif.), according to the manufacturer's instructions. Nav1.8 protein expression in the HEK293 cells was detected by westernimmunoblot analysis using a Nav1.8 specific peptide antibody, SOD1 (AnaSpec, San Jose, Calif.). The published peptide sequence was used for making the SOD1 antibody. See Novakovic et al., “Distribution of the tetrodotoxin-resistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions, J. Neuroscience, vol. 18, no. 6, pp. 2174-2187 (1998).
Knock-Down of Nav1.8 RNA
The five chemically synthesized siRNAs, SEQ ID NOs: 1-5, were individually co-transfected into HEK293 cells, along with the pcDNA-Nav1.8 control expression plasmid. The final siRNA concentration in the transfected cells was maintained at 25 nM. 24 hours after transfection, the cells were lysed and the total RNA was purified from lysates using RNAeasy minicolumns (Qiagen, Valencia, Calif.) according to the manufacturer's instructions. Total RNA purified from either cells cotransfected with the individual siRNAs or control cells were used for quantitative RT-PCR analysis using rat Nav1.8 specific Taqman® primer and probe sets (Applied Biosystems, Foster City, Calif.). Any rat Nav1.8 specific primer should work in this regard. The design of PCR primers is known in the art.
The expression level of Nav1.8 RNA in siRNA transfected cells was compared with RNA expression in control cells. The control cells, which were transfected with pcDNA3.1-Nav1.8 control expression plasmid, exhibited a relative rNav1.8 RNA expression level of 100%. The siRNA 1 cells, which were co-transfected with pcDNA3.1-Nav1.8 control expression plasmid and the siRNA of SEQ ID NO: 1, exhibited a relative rNav1.8 RNA expression level of 20%. The siRNA 2 cells, which were co-transfected with pcDNA3.1-Nav1.8 control expression plasmid and the siRNA of SEQ ID NO: 2, exhibited a relative rNav1.8 RNA expression level of 65%. The siRNA 3 cells, which were co-transfected with pcDNA3.1-Nav1.8 control expression plasmid and the siRNA of SEQ ID NO: 3, exhibited a relative rNav1.8 RNA expression level of 30%. The siRNA 4 cells, which were co-transfected with pcDNA3.1-Nav1.8 control expression plasmid and the siRNA of SEQ ID NO: 4, exhibited a relative rNav1.8 RNA expression level of 115%. The siRNA 5 cells, which were co-transfected with pcDNA3.1-Nav1.8 control expression plasmid and the siRNA of SEQ ID NO: 5, exhibited a relative rNav1.8 RNA expression level of 70%.
Cells co-transfected with either siRNA 1 or siRNA 3 showed high levels of Nav1.8 RNA silencing while cells co-transfected with either siRNA 2 and siRNA 5 showed moderate levels of RNA silencing. No knock-down in Nav1.8 RNA expression was seen in cells transfected with siRNA 4.
Knock-Down of Nav1.8 Protein
The five chemically synthesized siRNAs, SEQ ID NOs: 1-5, were individually co-transfected into HEK293 cells, along with the pcDNA-Nav1.8 control expression plasmid. The final siRNA concentration in the transfected cells was maintained at 25 nM. 24 hours after transfection, the cells were lysed in a denaturing lysis buffer and the lysates were run on denaturation 12% TBE gels (Invitrogen, Carsbad, Calif.). The gels were blotted onto nitrocellulose sheets and probed with the Nav1.8 specific antibody—SOD1 (AnaSpec, San Jose, Calif.).
Lysates from cells transfected with pcDNA-Nav1.8 control expression plasmid, the control cells, showed high levels of Nav1.8 protein expression. Lysates from cells co-transfected with pcDNA-Nav1.8 control expression plasmid and either siRNA 1 or siRNA 3 showed almost complete abolition of Nav1.8 protein expression. Lysates from cells co-transfected with pcDNA-Nav1.8 control expression plasmid and either siRNA 2 or siRNA 5 showed moderate levels of Nav1.8 protein expression. Lysates from cells co-transfected with pcDNA-Nav1.8 control expression plasmid and siRNA 4 showed no reduction in Nav1.8 protein expression.
Example 3
Next, we determined whether siRNA was capable of functionally knocking-down the Nav1.8 sodium channel. This determination was made using a FlexStation® assay (Molecular Devices, Sunnyvale, Calif.) and voltage clamp measurements. We stably expressed, by retroviral integration, the Nav1.8 coding sequence in the neuroblastoma/DRG fusion cell line ND7/23 (European Collection of Cell Cultures, Wiltshire, UK). The ND7/23 cell line is a mouse neuroblastoma and rat neurone hybrid, which is identified by European Collection of Cell Cultures No. 92090903. This ND7/23-Nav1.8 cell line showed consistent and high levels of Nav1.8 sodium current in both FlexStation® membrane potential assays and in whole cell voltage clamp measurements.
FlexStation® Assay
We individually transfected each of the above five selected siRNA sequences, SEQ ID NOs: 1-5, into the ND7/23-Nav1.8 cell line. Functional knock-down of Nav1.8 by the siRNAs was confirmed using the membrane potential assay on the FlexStation® according to the manufacturer's instructions. Readings on the FlexStation® were taken 1 day post transfection with individual siRNAs.
The luminescence level of control cells was compared to that of cells individually transfected with siRNAs 1-5. All cells were transfected with the Nav1.8 coding sequence. The control cells exhibited a luminescence level of 175,000 units. The siRNA 1 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 1, exhibited a luminescence level of 48,000 units. The siRNA 2 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 2, exhibited a luminescence level of 70,000 units. The siRNA 3 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 3, exhibited a luminescence level of 45,000. The siRNA 4 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 4, exhibited a luminescence level of 151,000. The siRNA 5 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 5, exhibited a luminescence level of 80,000.
siRNAs 1 and 3 blocked Nav1.8 derived membrane potential while siRNAs 2 and 5 showed moderate levels of blockage in membrane potential. siRNA 4 showed minimal or no blockage in membrane potential. The level of blockage in membrane potential by the individual siRNAs was similar to the level of both protein and RNA silencing by the siRNAs in the HEK293 system. In another example of this experiment, the control cells exhibited a luminescence level of 198,698 units. The siRNA 1 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 1, exhibited a luminescence level of 46,068 units (corresponding to 23% of control signal). The siRNA 2 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 2, exhibited a luminescence level of 71,523 units (corresponding to 36% of control). The siRNA 3 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 3, exhibited a luminescence level of 42,422 units (corresponding to 21% of control). The siRNA 4 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 4, exhibited a luminescence level of 151,067 units (corresponding to 76% of control). The siRNA 5 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 5, exhibited a luminescence level of 80,567 units (corresponding to 41% of control).
Voltage Clamp Measurements
To further confirm functional knock-down of Nav1.8 sodium currents, we performed whole cell voltage clamp measurements in ND7/23-Nav1.8 control cells that were subsequently transfected with siRNA 1. Briefly, ND7/23-Nav1.8 cells were either mock transfected with non-silencing siRNAs, the control cells, or transfected with siRNA 1, the siRNA 1 cells. The siRNA 1 concentration was maintained at 25 nM. Successfully transfected cells, which were identified by cotransfection with Green Fluorescent Protein (GFP) (Clontech, Palo Alto, Calif.), were used for whole cell voltage clamp measurements. Measurements were made both 24 and 48 hours post transfection.
At 24 hours post transfection, the control cells exhibited a peak amplitude of −900 while the siRNA 1 cells exhibited a peak amplitude of −175. At 48 hours post transfection, the control cells exhibited a peak amplitude of −775 while the siRNA 1 cells exhibited a peak amplitude of −175. Therefore, we observed almost total blockage in sodium currents in siRNA 1 transfected cells. In fact, the blockage was greater than 85%. Furthermore, the specificity of Nav1.8 block was confirmed by the observation that no block in tetrodotoxin-sensitive currents was seen in siRNA 1 treated ND7/23-Nav1.8 cells.
In another example, at 24 hours post transfection, the control cells (sample size=10) exhibited a mean peak whole-cell Na1.8 current amplitude of −912 pA while the siRNA 1 cells (sample size=11) exhibited a mean peak amplitude of −169 pA. Thus, by 24 h after transfection, siRNA1 had reduced the NaV1.8 current amplitude to 18.5% of control. Furthermore, the specificity of the siRNA effect to the intended tetrodotoxin-resistant Nav1.8 sodium channel was confirmed by the observation that no reduction in the amplitude of the background tetrodotoxin-sensitive sodium currents was seen in siRNA 1 treated ND7/23-Nav1.8 cells at either 24 or 48h post-transfection.
Example 4
In order to identify backup siRNAs that exhibit high levels of Nav1.8 knock-down, we designed six additional siRNAs, SEQ ID NOs: 6-11, in the region of the Nav1.8 coding sequences covering siRNA 1 and siRNA 3. These six additional siRNAs were designed using the same procedures outlined in Example 1, and have the following sequences, as shown in Table 5 below:








TABLE 5





sIRNA
Sequence

















siRNA 6
AAGAAGGCCAGAACCAAGCAC (SEQ ID NO: 6)



 


siRNA 7
AAGUUCUAUGGUGAGCUCCCA (SEQ ID NO: 7)


 


siRNA 8
AACUGGCUGGACUUCAGUGUC (SEQ ID NO: 8)


 


siRNA 9
AACUGUUUCUGUGAUCCCAGG (SEQ ID NO: 9)


 


siRNA 10
AAGGCUGACAACCUCUCAUCU (SEQ ID NO: 10)


 


siRNA 11
AAGAGUCUAAGCUGAAGUGCC (SEQ ID NO: 11)









All six additional siRNAs, SEQ ID NOs: 6-11, were screened for their ability to knock-down Nav1.8 derived membrane potential in ND7/23 cells. Using procedures similar to those in Example 3, the luminescence level of control cells was compared to that of cells individually transfected with siRNAs 6-11. The control cells exhibited a luminescence level of 175,000 units. The siRNA 6 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 6, exhibited a luminescence level of 85,000 units. The siRNA 7 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 7, exhibited a luminescence level of 50,000 units. The siRNA 8 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 8, exhibited a luminescence level of 45,000. The siRNA 9 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 9, exhibited a luminescence level of 43,000. The siRNA 10 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 10, exhibited a luminescence level of 10,000. The siRNA 11 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 11, exhibited a luminescence level of 35,000. Using procedures similar to those in Examples 2 and 3, we determined that all six siRNAs were also capable of blocking Nav1.8 expression and function, resulting in a collection of efficacious siRNAs.
In another example, the control cells exhibited a luminescence level of 198,698 units. The siRNA 6 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 6, exhibited a luminescence level of 86,105 units (43% of control cells). The siRNA 7 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 7, exhibited a luminescence level of 50,237 units (25% of control cells). The siRNA 8 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 8, exhibited a luminescence level of 44,038 units (22% of control cells). The siRNA 9 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 9, exhibited a luminescence level of 46,917 units (24% of control cells). The siRNA 10 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 10, exhibited a luminescence level of 21,847 (7% of control cells). The siRNA 11 cells, which were subsequently transfected with the siRNA of SEQ ID NO: 11, exhibited a luminescence level of 30,587 (15% of control cells).
Example 5
Adenoviral Delivery of Nav1.8 siRNA
For long term siRNA delivery to cells and knock-down of Nav1.8 function, we designed an adenoviral vector for driving siRNA expression. Briefly, the construct was designed to express siRNA 3 (SEQ ID NO: 3) under the control of a U6 promoter cassette. The siRNA 3 expression cassette was then cloned into an E1-deleted pTG4213 adenoviral backbone (Transgene SA, France).
ND7/23-Nav1.8 cells from Example 3 were infected with the above siRNA 3 adenoviral vector construct at a concentration of 1 e9 particles/ml. Control cells were infected at the same concentration with a control adenovirus containing a U6 promoter cassette. Infected cells were lysed for total RNA purification in order to perform either Taqman® assays or FlexStation® assays.
For Taqman® assays, Infected cells were lysed at 6, 8 and 10 days post infection (dpi), and RNA purifed from lysates was used to measure Nav1.8 RNA expression by quantitative RT-PCR analysis. At 6 days post infection, Nav1.8 RNA expression, expressed as a percentage of non-silencing adenoviral siRNA, was 18%. At 8 days post infection, Nav1.8 RNA expression, expressed as a percentage of non-silencing adenoviral siRNA, was 22%. At 10 days post infection, Nav1.8 RNA expression, expressed as a percentage of non-silencing adenoviral siRNA, was 30%.
For FlexStation® assays, infected cells were used for measuring Nav1.8 derived membrane potential on the FlexStation® at 2, 4, 6, 8 and 10 days post infection (dpi). At each time point, knock-down in membrane potential in siRNA 3 adenoviral vector construct infected cells was compared to membrane potential in control adenoviral infected cells. At 2 days post infection, percent sodium current, as compared to non-silencing adenoviral-siRNA, was 45%. At 4 days post infection, percent sodium current, as compared to non-silencing adenoviral-siRNA, was 15%. At 6 days post infection, percent sodium current, as compared to non-silencing adenoviral-siRNA, was 8%. At 8 days post infection, percent sodium current, as compared to non-silencing adenoviral-siRNA, was 8%. At 10 days post infection, percent sodium current, as compared to non-silencing adenoviral-siRNA, was 4%.
To further confirm that the reduction in RNA expression seen with the viral-siRNA construct was representative of an attenuation in function NaV1.8 sodium channel activity, we performed a number of whole-cell voltage clamp experiments to directly measure NaV1.8-mediated current at various times post-infection. In each of these experiments, current amplitudes were measured in a sample of ND7/23-NaV1.8 cells that had been previously infected with either a control, non-silencing siRNA construct ot with the adenoviral-siRNA 3 construct. At 4 days post infection with the non-silencing viral construct total mean (10 cells sampled) whole cell NaV1.8 current was −821 pA whilst that measured in siRNA3-virus infected cells was −101 pA (corresponding to 12.3% of control). At 6 days post infection, with the non-silencing viral construct total mean (10 cells sampled) whole cell NaV1.8 current was −932 pA whilst that measured in siRNA3-virus infected cells was −247.7 pA (corresponding to 26.6% of control). At 10 days post infection, with the non-silencing viral construct total mean (10 cells sampled) whole cell NaV1.8 current was −976.7 pA whilst that measured in siRNA3-virus infected cells was −542.7 pA (corresponding to 55.6% of control).
Thus, Taqman® and FlexStation® and voltage-clamp assays showed knock-down of Nav1.8 RNA expression and Nav1.8 derived membrane potential that lasted for at least 8 dpi. Infection by siRNA expressing adenovirus resulted in at least 80% knock-down of Nav1.8 expression and function. Thus, high levels of sustained Nav1.8 block were demonstrated using viral vectors for siRNA delivery.
Example 6
Effect of Nav1.8 siRNA in a Rat Model of Chronic Pain
The effect of Nav1.8-siRNA was investigated in a rat model of chronic pain using siRNA 3. Hind paw tactile sensitivity was measured in a cohort of rats using graded von-Frey microfilaments (=baseline sensitivity). The same rats were then subjected to a surgical procedure that entailed exposure of the left sciatic nerve at mid thigh level followed by a loose ligation injury effected using standard suture material. The wound was closed and the animals allowed to recover from the procedure for a period of at least one week prior to any subsequent behavioral evaluation. The nerve trauma resulting from the procedure resulted in a tactile hypersensitivity in the left hind paw, a condition that is referred to as tactile allodynia. The degree of allodynia is readily quantified using the same von-Frey filament procedure as used for the baseline measurements, such measurements were taken 13 days after the surgical day. In order to evaluate the effects of siRNA 3 (SEQ ID No 3) on the allodynia, the siRNA was delivered as a duplex into the intrathecal space around the spinal cord via a permanent indwelling intrathecal catheter. Two separate injections of 2 μg of siRNA 3 were made daily over a period of three days, control rats received an identical injection of vehicle only using the same timing protocol.
Baseline hindpaw sensitivities of rats used in these experiments ranged between 13 to 15 grams force. Thirteen days after the nerve trauma injury the hindpaw sensitivities were re-determined for each rat and were found to be in the range of 1.2±0.4 g in the cohort designated the siRNA group and 2.1±0.4 g in the control cohort (cohort size=6 rats in drug-treated group and 5 rats in the control group). Nerve injury resulted, therefore, in a profoundly painful tactile hypersensitivity (allodynia) that is typical of that seen in human subjects having suffered injuries that lead to a chronic neuropathic pain state. Regular assessments revealed the painful allodynic state to be maintained (typically <2.1 g) through days 13 to 21 in the control cohort of rats that received vehicle-only injections. By contrast, rats that were injected with siRNA 3 for three days, commencing immediately after their day 13 assessment, showed a pronounced reversal of their painful allodynia (8.1±2.1 g, assessed on day 16). Rats treated with siRNA 3 showed a consistently improved pain score, (e.g., an amelioration of an experimentally-induced chronic pain state) compared to controls, over several subsequent days during which measurements were taken.

## Claims

1. An isolated or recombinant short interfering nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1, or an analogue thereof.

2. The isolated or recombinant short interfering nucleic acid of claim 1 comprising the nucleotide sequence of SEQ ID NO: 1.

3. The isolated or recombinant short interfering nucleic acid of claim 1 comprising the nucleotide sequence of an analogue of SEQ ID NO: 1.

4. The isolated or recombinant short interfering nucleic acid of claim 2, further comprising a 3′ overhang.

5. The isolated or recombinant short interfering nucleic acid of claim 3, further comprising a 3′ overhang.

6. A pharmaceutical composition comprising the short interfering nucleic acid of claim 1, and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising the short interfering nucleic acid of claim 2, and a pharmaceutically acceptable carrier.

8. The isolated or recombinant short interfering nucleic acid of claim 1, further comprising a complementary nucleotide sequence thereto.

9. The complementary nucleotide sequence of claim 8, further comprising a 3′ overhang.

10. A pharmaceutical composition comprising the short interfering nucleic acid and complementary nucleotide sequence of claim 8, and a pharmaceutically acceptable carrier.

11. The isolated or recombinant short interfering nucleic acid of claim 8, wherein said nucleotide sequence and said complementary nucleotide sequence hybridize to form a duplex.

12. The duplex of claim 11, wherein said nucleotide sequence further comprises a 3′ overhang and said complementary nucleotide sequence further comprises a 3′ overhang.

13. A pharmaceutical composition comprising the duplex of claim 11, and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising the duplex of claim 12, and a pharmaceutically acceptable carrier.

15. A pharmaceutical composition comprising the short interfering nucleic acid and complementary nucleotide sequence of claim 9, and a pharmaceutically acceptable carrier.

16. An isolated or recombinant short interfering nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1 and a complementary nucleotide sequence thereto.

17. The complementary nucleotide sequence of claim 16, further comprising a 3′ overhang.

18. A pharmaceutical composition comprising the short interfering nucleic acid and complementary nucleotide sequence of claim 16, and a pharmaceutically acceptable carrier.

19. The isolated or recombinant short interfering nucleic acid of claim 16, wherein said nucleotide sequence and said complementary nucleotide sequence hybridize to form a duplex.

20. The duplex of claim 19, wherein said nucleotide sequence further comprises a 3′ overhang and said complementary nucleotide sequence further comprises a 3′ overhang.

21. A pharmaceutical composition comprising the duplex of claim 19, and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising the duplex of claim 20, and a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising the duplex of claim 17, and a pharmaceutically acceptable carrier.

24. A recombinant vector comprising the nucleotide sequence of claim 1.

25. A recombinant vector comprising the nucleotide sequence of claim 2.